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Iron overload has been proposed to be a component of the insulin-resistance 
syndrome. On the other hand, dietary iron supplementation is associated with growth 
and increased appetite in children. We found the concentration of circulating ferritin is 
associated with low serum adiponectin, the insulin-sensitizing adipokine, and leptin, the 
adipokine that is responsible for regulating food intake. Similarly, mice fed a high iron 
diet and 3T3-L1 adipocytes treated with iron exhibited decreased adiponectin and leptin 
mRNA and protein.  
Iron negatively regulates transcription of adiponectin promoter-driven luciferase 
activity in a FOXO1-dependent manner. However, iron decreases the inactivated form 
of FOXO1, acetyl-FOXO1, while leaving phosphorylated FOXO1 and total FOXO1 
unaffected. The mechanism of iron’s effect on adiponectin and promotion of metabolic 
syndrome is demonstrated via the binding affinity of multiple transcription factors in the 
adiponectin promoter using ChIP studies. The higher activation of FOXO1 in iron-
treated cells contributes to more inactivation of PPARγ through direct interaction, 
leading to decreased adiponectin transcription and expression. These findings directly 
demonstrate a causal role for iron as a risk factor for metabolic syndrome and a role for 
adipocytes in modulating metabolism through adiponectin in response to iron stores.  
We found iron negatively regulated leptin transcription via cAMP response 
element binding protein (CREB) activation. Two potential CREB-binding sites were 
identified in the mouse leptin promoter region. Mutation of both sites completely blocked 
the effect of iron on promoter activity. We also found enrichment of phospho-CREB 
  iv 
binding to those two sites by ChIP in 3T3-L1 adipocytes treated with iron. CREB is 
modified and destabilized by O-GlcNAc modification. Iron also negatively regulates O-
GlcNAc modification both in 3T3-L1 and epididymal fat, and mice heterozygous for 
deletion of the gene encoding the enzyme that removes O-GlcNAc, O-GlcNAcase, 
showed significantly increased serum leptin compared to wild-type mice. Glucosamine 
treatment rescued high iron-induced decrease of leptin promoter activity. These results 
suggest that the effects of iron on leptin may be via crosstalk of O-GlcNAcylation and 
phosphorylation of CREB. These findings indicate that levels of dietary iron play an 
important role in regulation of appetite and fat metabolism through CREB-dependent 
modulation of leptin expression. 
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Type 2 Diabetes Mellitus (T2DM) is major health problem in the United States 
and the world. Epidemiological studies have shown a positive correlation between iron 
levels in the body and insulin resistance (1). The mechanisms underlying these 
associations are largely unknown. Iron can contribute to hyperglycemia via reducing 
insulin secretion by islets or decreasing insulin sensitivity in muscle and adipose tissue. 
One hormone well recognized as a regulator of glucose homeostasis is adiponectin, a 
regulator of metabolism in many tissues that also sensitizes them to insulin. It is largely 
secreted by adipose tissue. It can activate 5' AMP-activated protein kinase (AMPK) that 
turns on fatty acid oxidation and increases glucose uptake in skeletal muscle. In liver, 
activation of AMPK by adiponectin can decrease glucose output through repressing 
gluconeogenesis via decreasing the genes encoding phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase) (2). Opposite to iron, 
adiponectin levels are lower in patients with insulin resistance and T2DM, and 
decreased adiponectin levels have been causally linked to insulin resistance (3). We 
therefore hypothesized that iron and adiponectin are interrelated, and that adiponectin 
may be a mediator of iron’s effect on insulin resistance. Supporting this, recent 
epidemiologic studies have found a negative correlation between serum ferritin and 
adiponectin levels (4-7).  
Our lab therefore investigated the effect of iron on adiponectin and the 
mechanism of iron-induced decreases in adiponectin. We demonstrate in humans that 
the association between serum ferritin and adiponectin is independent of inflammation. 





   
adiponectin levels. Studies in cell culture, mouse models, and humans demonstrate that 
iron plays a direct and causal role in determining adiponectin levels. I have 
demonstrated the decrease of adiponectin transcription is via FOXO1-mediated 
repression of PPARγ occupancy on its promoter. The adipocyte responding to iron 
availability and adjusting expression of adipokines related to metabolism make it well 
suited to perform its broader nutrient-sensing function. 
Obesity is also a national epidemic and currently affects about 1 out of 3 adults 
and 1 out of 6 children in the United States and accounts for 10% of the U.S. medical 
budget. Obesity and its related metabolic disorders are one of the leading causes of 
mortality in adult humans in the United States (8) and contributes to the risk for 
cardiovascular diseases (heart attack and stroke), T2DM, and some types of cancer. 
Obesity is characterized by increased adipose tissue mass. Unlike other tissues in the 
body, adipose tissue, typically known as a primary site for energy storage, constantly 
changes its size and distribution throughout adulthood because of changes in metabolic 
demand and caloric intake. Adipose tissue also functions as the largest endocrine 
organ, regulating metabolism through the secretion of many adipokines such as leptin, 
adiponection, tumor necrosis factor-α, and others. It is therefore not surprising that 
structural and functional alterations of the adipose tissue have been shown to have a 
severe impact on metabolism in the body. The developmental biology of adipose tissue 
is also important: Weight gain and obesity can be seen as cases of adipose over-
development, wherein the need for maturation of adipocytes from preadipocytes is 
accelerated or even overwhelmed (9). Despite intense efforts to fully understand 
adipogenesis, however, an effective approach or drug to prevent and treat obesity is 
still lacking (10). 
Much has been learned about obesity through studying rare and/or specific 





   
to the molecular definition of hypothalamic appetite regulation. Leptin is a hormone that 
is secreted primarily by adipose tissue and responsible for regulating feeding behavior. 
It is also a commonly used marker for total body fat and positively associated with body 
mass index (BMI). Elevated leptin levels play a central role in weight control through 
suppressing food intake and increasing energy expenditure (11). Scientific reports have 
shown iron plays a role in the regulation of appetite. Dietary iron supplementation is 
associated with growth and increased appetite in children (12, 13). The mechanism 
underlying this association is poorly understood. Low serum leptin levels have been 
linked to tissue iron overload (14, 15), and obesity is epidemiologically associated with 
iron deficiency (16). However, the possible mediators of the associations among iron 
and leptin levels are unknown.  
On the other hand, iron deficiency is more prevalent in obese compared to 
normal weight individuals. If leptin is responsive to iron, decreased leptin in high iron 
consumption but lower adiposity may hide the association of iron and leptin. However, 
the adipocytes of β thalassemia major patients also fail to maintain adequate leptin 
production (17). The association between BMI and serum leptin levels is dampened or 
even abolished in transfusion-treated thalassemic patients (18), arguing iron may play a 
causal role in serum leptin independent of body weight. Dietary-induced obesity in vivo 
may be the outcome of increased leptin with decreased iron storage and leptin 
resistance (19). Furthermore, the clinically used biomarker for total body iron stores, 
soluble transferrin receptor (sTfR), is negatively associated with serum leptin (20). 
Serum ferritin, an iron storage protein, correlates significantly with appetite score 
(r=0.680, P <0.001) and food intake (r =0.480, P < 0.01) (21), suggesting iron may play 
a role in feeding behavior through reducing serum leptin.  
In this introduction, I will review studies linking iron and adipocyte. I will describe 





   
and obesity. Next, I will review the role of adipocytes in feeding behavior regulation, 
with particular emphasis on the satiety hormone, leptin. I will conclude by reviewing iron 




Iron is an essential constituent of many macromolecules involved in cell 
metabolism. Mammalian cells require iron for survival and proliferation. In general, an 
adult stores about 1 to 3 grams of iron in his or her body, and a balance between 
dietary uptake and loss is precisely regulated in healthy humans. About 1 to 3 mg of 
iron is lost daily through bleeding (e.g. menstruation in adult females) and sloughing of 
cells from skin and mucosal surfaces in the lining of the gastrointestinal tract (22, 23). 
However, there is no defined physiological means of active iron excretion. If intake of 
iron from the diet is not sufficiently compensated by loss of iron, a state of iron overload 
develops over time. Therefore, exquisite manipulation of iron absorption is crucial for 
the regulation of iron stores. Much of the iron in the lumen of the duodenum is in the 
ferric form. However, iron is mainly absorbed in mature villous enterocytes of the 
duodenum and upper jejunum via the brush border iron transporter divalent metal 
transporter 1 (DMT1) in the form of ferrous ion (24). Therefore, ferric ion must be 
reduced before it can enter enterocytes. The reduction of iron is probably carried out by 
the brush border enzyme, ferric reductase. Once iron enters enterocytes, it can be 
readily exported to the circulation through the iron transport protein ferroportin 1 (Fpn1), 
which is also the main iron export transporter in other cell types, including 
macrophages. When iron levels are high in the circulation, iron in enterocytes will not be 
transferred to the bloodstream because of reduction of ferroportin at the cell surface. 
The iron is then incorporated into the iron storage molecule, ferritin, and is lost when the 





   
expression in macrophages and enterocytes is hepcidin, which is mainly secreted from 
the liver. Hepcidin causes endocytosis and degradation of ferroportin, leading to 
sequestration of iron in enterocytes and protection from excess iron entering the 
circulation (25) (26). The so-called hepcidin-ferroportin axis is thus tightly regulated.  
 
Adipokines and insulin sensitivity 
 
Adipokines are a group of growth factors, hormones, and cytokines produced by 
mature adipocytes. Many of those factors are involved in diverse processes in the body, 
including glucose and lipid homeostasis, modulation of inflammatory responses, body 
weight control, blood pressure, and other diabetes-associated alterations such as 
inflammation (27). 
People with metabolic syndrome—a collection of disorders including obesity, 
insulin resistance, hypertension, and abnormal glucose and lipid metabolism—display a 
characteristic imbalance of their adipokine profile. This altered adipokine profile 
functions through autocrine, paracrine, and endocrine mechanisms to lead to increased 
inflammation, decreased insulin sensitivity, and other metabolic disorders when the 
adipocytes are stressed by nutrient overload and obesity.  
Two major adipocytokines, leptin and adiponectin, play a vital role in the 
regulation of metabolic homeostasis. Leptin acts directly on the leptin-receptor in the 
hypothalamus, thereby decreasing food intake and increasing energy expenditure (28). 
Plasma leptin concentrations are significantly elevated in obese people in proportion to 
BMI (29), and the chronically elevated results in leptin resistance may play a role in the 
pathogenesis of obesity-related complications (30). Obese subjects also preferentially 
secrete a low molecular weight isoform of adiponectin, which is not as effective as the 
larger isoforms, which also contributes to low rates of fat oxidation, failure to clear 





   
decreasing insulin sensitivity (31).  
Metabolic syndrome is characterized by leptin resistance and low adiponectin, 
and thus decreased action of both hormones. Leptin and adiponectin activate AMPK 
and facilitate glucose uptake in muscle and repress gluconeogenesis in liver (32, 33). 
AMPK then phosphorylates and inhibits acetyl coenzyme-A carboxylase (ACC) in 
skeletal muscle and liver which results in lower rates of fatty acid synthesis. AMPK also 
activates peroxisome proliferator–activated receptor (PPAR) α and its targeted genes 
involved in peroxisomal and mitochondrial β-oxidation such as ACO, CPT1, and 
FABP3(34-37). Therefore, leptin and adiponectin levels serve as indices for metabolic 
homeostasis.  The changes in each individual adipokine are the result of one or more 
changes of specific transcriptional programs that affect adipocyte gene control.  
 
Iron overload and diabetes 
 
It is well established that iron overload is associated with high risk of diabetes, 
including hyperglycemia, insulin resistance, chronic inflammation, and altered levels of 
adipokines (38). The first evidence showing increased iron deposition could contribute 
to hyperglycemia derived from the observation that the incidence of diabetes is higher 
in classic hereditary hemochromatosis (HH) (39, 40). Conversely, a causal role of iron 
overload in increasing insulin sensitivity was suggested in a cohort of subjects with 
frequent blood donation and decreased iron stores (41, 42). The role of iron in the 
pathogenesis of diabetes was further reinforced by the finding of an increased 
incidence of T2DM in increased iron deposition and improvement in glucose control 
with either phlebotomy or iron chelation therapy in a diverse set of medical conditions. 
For example, transfusional iron overload is a common cause of acquired iron overload, 
such as is seen in β-thalassemia patients. Impaired glucose tolerance (8.5%) and 





   
and 19.5%, respectively (43). One risk factor for impaired glucose tolerance and T2DM 
was high serum ferritin.  
Our laboratory has also found that iron overload results in elevated beta-cell 
oxidative stress and apoptosis, and desensitization of glucose-induced insulin secretion 
from mouse pancreatic islets, all of which result in decreased insulin secretory 
responses (44, 45). Conversely, impaired insulin secretory capacity may be attenuated 
by therapeutic iron chelation (46). However, the insulin secretion defect caused by iron 
overload is compensated by changes in insulin sensitivity such that these mice 
demonstrate normal glucose tolerance (45, 47, 48). 
 
Iron deficiency and obesity 
 
Obesity and iron deficiency are two common nutritional and health problems in 
the world and major cofactors in many other diseases. Obesity is a reflection of energy 
imbalance between expenditure and intake in the forms of increased fat accumulation. 
Excess body fat is correlated with increased all-cause mortality and increased risk for 
several medical morbidities (49). The foremost medical consequence of obesity is 
cardiovascular disease (CVD), which is also the leading cause of death in this country 
(50). It is urgent to develop new and effective strategies in controlling obesity and find 
potential targets for weight control.  
Several studies have shown a greater prevalence of iron deficiency in 
overweight and obese people than normal-weight ones (51-55). Analysis of public-use 
data files indicated there is a negative relationship between levels of iron blood content 
and individual BMI after controlling for other individual characteristics (56).  
The etiology of iron deficiency-associated obesity remains unknown. Several 
hypotheses have been put forth to explain the occurrence of obesity in iron deficiency. 





   
related to: (i) decreased iron intake associated with obesogenic diets or lifestyles; (ii) 
impairment of intestinal iron absorption and a reduced response to iron fortification in 
obesity (57); (iii) reduced iron release from iron stored cells and iron bioavailability (58, 
59). Other studies indicate that iron may play a causal role in obesity. One report, for 
example, showed rats on an iron-deficient diet gained more fat mass than paired mice 
fed an iron-replete diet (60). We have investigated the mechanisms of iron’s effects on 
lipid and carbohydrate metabolism in the liver and muscle. Muscle from mice on a low 
iron diet, for example, exhibits increased fatty acid synthesis but decreased lipolysis 
and fatty acid oxidation (61). On the other hand, iron overload mice change fuel usage 
from glucose to fatty acid oxidation in the muscle. Decreased glucose uptake and 
increased liver glucose production contribute to hyperglycermia in iron overloaded mice 
(62). 
 
Hereditary hemochromatosis, type I 
 
Hereditary hemochromatosis (HH), an autosomal recessive disorder of iron 
overload, is one of the most common genetic diseases in the Caucasian population. 
Symptoms are usually nonspecific or absent in the early development of HH, but 
progressive tissue iron overload may cause irreversible organ damage as patients age. 
A missense mutation in the HFE gene (C282Y) comprises up to 90% of HH cases (63). 
Mutation in HFE gene results in extremely low serum hepcidin levels, resulting in 
unregulated iron absorption from the gut and increased serum ferritin and transferrin 
saturation. Typical treatment for HH is phlebotomy or the use of iron chelators, with the 
frequency of treatment being guided by serial measurement of the above two indicators. 
The liver is the main organ that recycles iron from senescent erythrocytes and 
hepatocytes storage pools and releases iron according to the body’s needs. It also 





   
regulation of hepcidin expression is the central point for maintaining the iron balance. 
Under low iron conditions, the HFE protein is associated with transferrin receptor 1 
(TFR1). When iron level goes up, transferrin-Fe complex competes with HFE for the 
binding site in the TFR1 since they have the same binding site, while HFE then binds 
with transferrin receptor 2 (TFR2), which recruits the hemojuvelin (HJV)-SMAD 
signaling pathway (64, 65). Bone morphogenetic proteins (BMPs) are members of the 
TGF-β superfamily and they signal through BMP receptors (BMPRs) to cytoplasmic 
SMAD protein transcription factors. Interestingly, HJV is a BMP co-receptor. Disruption 
or mutation of HJV also leads to hemochromatosis and reduction of hepcidin, indicating 
HJV’s BMP signaling is critical for the regulation of hepcidin (66). Phosphorylation of 
serine/threonine kinase in BMPRs activates SMADs, including SMAD1, SMAD4, and 
SMAD8, causing translocation of SMADs to the nucleus and increase of the expression 
of target genes containing SMAD-binding elements. One of the most important genes is 
HAMP gene, which encodes hepcidin protein (Figure 1.1).  
 
Obesity and leptin resistance  
 
Obesity is an over-development of adipose tissue, with both hyperplasia 
(increased cell number) and hypertrophy (increased cell size) contributing to the excess 
fat (67, 68). Recently, efforts and progress have been made in understanding the 
process of adipocyte differentiation. These studies have laid the foundation for the 
understanding of the cellular and molecular basis of adipose tissue growth in 
physiological and/or patho-physiological states and provide a potential target to develop 
therapeutic strategies for the treatment and prevention of obesity. It has also been 
reported that transformation of adipocytes from cells that store triglycerides to cells that 
oxidize fatty acids results in profound loss of fat (69). Those transformed adipocytes, 





   
characterized by increased expression of enzymes of fatty acid oxidation and 
uncoupling proteins accompanied by loss of the adipocyte markers, tumor necrosis 
factor α and leptin. However, hyperleptinemia by itself does not eliminate excess fat in 
obese mice, indicating resistance of leptin action in obesity (70). 
Leptin normally exerts negative feedback effects on food intake and positive 
feedback on energy expenditure (28, 71, 72). Leptin acts through the leptin receptor 
(ObR) (73). Animals with diet-induced obesity, however, are not leptin deficient. In 
contrast, they usually present high circulating leptin concentrations. Furthermore, leptin 
treatment of obesity fails to reduce energy intake and increase energy expenditure. This 
state is termed leptin resistance.  
There are two dominant hypotheses that have been advanced to explain leptin 
resistance. One is that circulating leptin fails to transport to the brain to reach its target 
(74, 75), and the other is the failure of the leptin and leptin receptor signaling cascade 
(76). However, the detailed mechanism of leptin resistance is still not clearly 
investigated. Leptin resistance has been widely reported to be a consequence of 
obesity (77, 78), although emerging evidence also suggests that leptin resistance may 
not be purely a result of obesity, but also involved in its causation. For example, 
overexpression of leptin in specific tissues can result in induction of early leptin 
resistance (79), and inherent central leptin insensitivity contributes to dietary weight 
gain in certain obesity-prone rats (80). Therefore, more studies are required to explore 
the relationship between obesity and leptin.  
 
Leptin and iron 
 
Studies, both in healthy humans and patients with iron overload, have reported 
that high ferritin is associated with a decrease in plasma leptin levels (15). Another 





   
negatively associated with serum leptin (20). The adipocytes of patients with β 
thalassemia major, who are iron overloaded because of numerous blood transfusions, 
fail to maintain adequate leptin production (14, 15, 17, 20). In addition, we have also 
recently demonstrated that another adipokine, adiponectin, is regulated by iron, so 
there is precedent for possible regulation of leptin (81). As discussed in a previous 
section, epidemiologic studies suggest a relationship between iron deficiency and 
increased rates of obesity. We hypothesize that leptin deficiency and/or resistance may 
provide one link between dietary iron and obesity. If leptin is also responsive to iron, 
increased leptin in the population with low iron consumption but higher adiposity may 
hide the association of iron and leptin, since the high leptin could result from either. 
However, the association between BMI and serum leptin levels is dampened or even 
abolished in transfusion-treated β thalassemic patients (18), arguing iron may play a 
causal role in contributing to the levels of serum leptin. Dietary-induced obesity 
association in vivo thus may be the outcome of increased leptin with decreased iron 
storage and leptin resistance (19). Furthermore, serum ferritin, an iron storage protein, 
correlates significantly with appetite score (r = 0.680, P < 0.001) and food intake (r = 
0.480, P < 0.01) (21), suggesting iron may play a role in feeding behavior through 
decreasing serum leptin.  
 
Hexosamine biosynthesis pathway (HBP) 
 
The HBP is a glucose metabolic pathway, usually accounting for only 2–5% of 
total glucose metabolism. The major product is UDP-N-acetylglucosamine (UDP-
GlcNAc). UDP-GlcNAc is the unique donor for the modification of many cytoplasmic 
and nuclear proteins by O-linked GlcNAcylation, wherein a single N-acetylglucosamine 
molecule is transferred to serine or threonine (O-GlcNAc). Glucose entering the 





   
fructose-6-phosphate (F6P). The latter is then diverted to the HBP by the first and rate-
limiting enzyme of the pathway, glutamine: fructose-6-phosphate amidotransferase 
(GFAT) that catalyzes the synthesis of glucosamine-6-phosphate. Subsequently, the 
addition of an acetyl moiety from acetyl-CoA yields N-acetyl glucosamine-6-phosphate, 
and the latter is rapidly modified to UDP-GlcNAc. Thus, substrate production in the HBP 
reflects cellular amino acid, fatty acid, and nucleotide metabolism, and there is evidence 
that it is rate limited at least by glucose and uridine. UDP-GlcNAc is then used as the 
substrate for the O-GlcNAcylation modification of proteins catalyzed by O-GlcNAc 
transferase (OGT). This modification is reversible and the removal of O-GlcNAc is via 
O-GlcNAcase (OGA). The HBP is precisely regulated via negative feedback circuits. 
The accumulated end product, UDP-GlcNAc, decreases GFAT activity and also 
modulates the affinity of OGT for individual substrates (82). Sites that are targets of O-
GlcNAcylation are at or near sites of O-phosphorylation. Extensive crosstalk exists 
between O-GlcNAcylation and phosphorylation in organisms and contributes to 
signaling change in response to nutrients and a variety of stressors (83). While 
phosphorylation and dephosphorylation are catalyzed by a multitude of specific and 
distinct kinases and phosphatases, O-GlcNAcylation and its removal are catalyzed by 
products of single genes for OGA and OGT in mammals. O-GlcNAcylation cycles on 
and off nucleocytoplasmic proteins in response to different physiological stimuli, such 
as hormones, growth factors, and mitogens (84). About 600 targets have been 
identified, but little is known about the functional significance of their modification (85). 
O-GlcNAc directly regulates the activities of a variety of transcription factors, including 
Sp1 (86), CREB (87), members of the fork-head (FOXO) family  (88), and others. Those 
changes may contribute to development of insulin resistance (89), glucose toxicity(90), 
heart failure (91), and memory loss (87), but a direct role and/or mechanisms remain to 





   
 








   
References 
1. Wlazlo, N., van Greevenbroek, M.M., Ferreira, I., Jansen, E.H., Feskens, E.J., 
van der Kallen, C.J., Schalkwijk, C.G., Bravenboer, B., and Stehouwer, C.D. 2013. Iron 
metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the 
Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care 
36:309-315. 
 
2. Lihn, A.S., Pedersen, S.B., and Richelsen, B. 2005. Adiponectin: action, 
regulation and association to insulin sensitivity. Obes Rev 6:13-21. 
 
3. Kubota, N., Terauchi, Y., Yamauchi, T., Kubota, T., Moroi, M., Matsui, J., Eto, 
K., Yamashita, T., Kamon, J., Satoh, H., et al. 2002. Disruption of adiponectin causes 
insulin resistance and neointimal formation. J Biol Chem 277:25863-25866. 
 
4. Forouhi, N.G., Harding, A.H., Allison, M., Sandhu, M.S., Welch, A., Luben, R., 
Bingham, S., Khaw, K.T., and Wareham, N.J. 2007. Elevated serum ferritin levels 
predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. 
Diabetologia 50:949-956. 
 
5. Fargnoli, J.L., Fung, T.T., Olenczuk, D.M., Chamberland, J.P., Hu, F.B., and 
Mantzoros, C.S. 2008. Adherence to healthy eating patterns is associated with higher 
circulating total and high-molecular-weight adiponectin and lower resistin 
concentrations in women from the Nurses' Health Study. Am J Clin Nutr 88:1213-1224. 
 
6. Mojiminiyi, O.A., Marouf, R., and Abdella, N.A. 2008. Body iron stores in relation 
to the metabolic syndrome, glycemic control and complications in female patients with 
type 2 diabetes. Nutr Metab Cardiovasc Dis 18:559-566. 
 
7. Ku, B.J., Kim, S.Y., Lee, T.Y., and Park, K.S. 2009. Serum ferritin is inversely 
correlated with serum adiponectin level: population-based cross-sectional study. Dis 
Markers 27:303-310. 
 
8. Cao, Y. 2007. Angiogenesis modulates adipogenesis and obesity. J Clin Invest 
117:2362-2368. 
 
9. Isakson, P., Hammarstedt, A., Gustafson, B., and Smith, U. 2009. Impaired 
preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis 
factor-alpha, and inflammation. Diabetes 58:1550-1557. 
 
10. Cao, Y. 2010. Adipose tissue angiogenesis as a therapeutic target for obesity 
and metabolic diseases. Nat Rev Drug Discov 9:107-115. 
 
11. Gamber, K.M., Huo, L., Ha, S., Hairston, J.E., Greeley, S., and Bjorbaek, C. 
2012. Over-expression of leptin receptors in hypothalamic POMC neurons increases 
susceptibility to diet-induced obesity. PLoS One 7:e30485. 
 
12. Lawless, J.W., Latham, M.C., Stephenson, L.S., Kinoti, S.N., and Pertet, A.M. 
1994. Iron supplementation improves appetite and growth in anemic Kenyan primary 






   
13. Stoltzfus, R.J., Chway, H.M., Montresor, A., Tielsch, J.M., Jape, J.K., Albonico, 
M., and Savioli, L. 2004. Low dose daily iron supplementation improves iron status and 
appetite but not anemia, whereas quarterly anthelminthic treatment improves growth, 
appetite and anemia in Zanzibari preschool children. J Nutr 134:348-356. 
 
14. Karachaliou, F., Vlachopapadopoulou, E., Theochari, M., Konstandellou, E., and 
Michalados, S. 2006. Leptin levels in patients with thalassemia major. Minerva Pediatr 
58:373-378. 
 
15. Perrone, L., Perrotta, S., Raimondo, P., Mucerino, J., De Rosa, C., Siciliani, 
M.C., Santoro, N., and Miraglia del Giudice, E. 2003. Inappropriate leptin secretion in 
thalassemia: a potential cofactor of pubertal timing derangement. J Pediatr Endocrinol 
Metab 16:877-881. 
 
16. Bourque, S.L., Komolova, M., McCabe, K., Adams, M.A., and Nakatsu, K. 2012. 
Perinatal iron deficiency combined with a high-fat diet causes obesity and 
cardiovascular dysregulation. Endocrinology 153:1174-1182. 
 
17. Choobineh, H., Dehghani, S.J., Alizadeh, S., Dana, V.G., Saiepour, N., 
Meshkani, R., and Einollahi, N. 2009. Evaluation of leptin levels in major beta-
thalassemic patients. Int J Hematol Oncol Stem Cell Res 3:1-4. 
 
18. Miraglia Del Giudice, E., Perrotta, S., Carbone, M.T., Calabro, C., Esposito, L., 
De Rosa, C., Saviano, A., Di Toro, R., and Perrone, L. 1999. Evaluation of leptin protein 
levels in patients with Cooley's anaemia. Br J Haematol 105:839-840. 
 
19. Chung, J., Kim, M.S., and Han, S.N. 2011. Diet-induced obesity leads to 
decreased hepatic iron storage in mice. Nutr Res 31:915-921. 
 
20. Dedoussis, G.V., Kyrtsonis, M.C., Andrikopoulos, N.E., Voskaridou, E., and 
Loutradis, A. 2002. Inverse correlation of plasma leptin and soluble transferrin receptor 
levels in beta-thalassemia patients. Ann Hematol 81:543-547. 
 
21. Topaloglu, A.K., Hallioglu, O., Canim, A., Duzovali, O., and Yilgor, E. 2001. Lack 
of association between plasma leptin levels and appetite in children with iron deficiency. 
Nutrition 17:657-659. 
22. Bothwell, T.H., and Charlton, R.W. 1982. A general approach to the problems of 
iron deficiency and iron overload in the population at large. Semin Hematol 19:54-67. 
 
23. Cook, J.D., Skikne, B.S., Lynch, S.R., and Reusser, M.E. 1986. Estimates of 
iron sufficiency in the US population. Blood 68:726-731. 
 
24. Muir, A., and Hopfer, U. 1985. Regional specificity of iron uptake by small 
intestinal brush-border membranes from normal and iron-deficient mice. Am J Physiol 
248:G376-379. 
 
25. Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., 
Ganz, T., and Kaplan, J. 2004. Hepcidin regulates cellular iron efflux by binding to 
ferroportin and inducing its internalization. Science 306:2090-2093. 
 





   
27. Deng, Y., and Scherer, P.E. 2010. Adipokines as novel biomarkers and 
regulators of the metabolic syndrome. Ann N Y Acad Sci 1212:E1-E19. 
 
28. Friedman, J.M., and Halaas, J.L. 1998. Leptin and the regulation of body weight 
in mammals. Nature 395:763-770. 
 
29. Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., 
Nyce, M.R., Ohannesian, J.P., Marco, C.C., McKee, L.J., Bauer, T.L., et al. 1996. 
Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N 
Engl J Med 334:292-295. 
 
30. Muoio, D.M., Dohm, G.L., Fiedorek, F.T., Jr., Tapscott, E.B., and Coleman, R.A. 
1997. Leptin directly alters lipid partitioning in skeletal muscle. Diabetes 46:1360-1363. 
 
31. Matsuzawa, Y., Funahashi, T., Kihara, S., and Shimomura, I. 2004. Adiponectin 
and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33. 
 
32. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., 
Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. 2001. The fat-derived hormone 
adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. 
Nat Med 7:941-946. 
 
33. Minokoshi, Y., Kim, Y.B., Peroni, O.D., Fryer, L.G., Muller, C., Carling, D., and 
Kahn, B.B. 2002. Leptin stimulates fatty-acid oxidation by activating AMP-activated 
protein kinase. Nature 415:339-343. 
 
34. Tugwood, J.D., Issemann, I., Anderson, R.G., Bundell, K.R., McPheat, W.L., 
and Green, S. 1992. The mouse peroxisome proliferator activated receptor recognizes 
a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. 
EMBO J 11:433-439. 
 
35. Zhang, B., Marcus, S.L., Sajjadi, F.G., Alvares, K., Reddy, J.K., Subramani, S., 
Rachubinski, R.A., and Capone, J.P. 1992. Identification of a peroxisome proliferator-
responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA 
hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc Natl Acad Sci U S A 89:7541-7545. 
 
36. Gulick, T., Cresci, S., Caira, T., Moore, D.D., and Kelly, D.P. 1994. The 
peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative 
enzyme gene expression. Proc Natl Acad Sci U S A 91:11012-11016. 
 
37. Rodriguez, J.C., Gil-Gomez, G., Hegardt, F.G., and Haro, D. 1994. Peroxisome 
proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-
methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem 269:18767-18772. 
 
38. Simcox, J.A., and McClain, D.A. 2013. Iron and diabetes risk. Cell Metab 
17:329-341. 
 
39. Creighton Mitchell, T., and McClain, D.A. 2014. Diabetes and hemochromatosis. 






   
40. Dubois-Laforgue, D., Caillat-Zucman, S., Boitard, C., and Timsit, J. 2000. 
Clinical characteristics of type 2 diabetes in patients with mutations of HFE. Diabetes 
Metab 26:65-68. 
 
41. Jiang, R., Ma, J., Ascherio, A., Stampfer, M.J., Willett, W.C., and Hu, F.B. 2004. 
Dietary iron intake and blood donations in relation to risk of type 2 diabetes in men: a 
prospective cohort study. Am J Clin Nutr 79:70-75. 
 
42. Fernandez-Real, J.M., Lopez-Bermejo, A., and Ricart, W. 2005. Iron stores, 
blood donation, and insulin sensitivity and secretion. Clin Chem 51:1201-1205. 
 
43. Chern, J.P., Lin, K.H., Lu, M.Y., Lin, D.T., Lin, K.S., Chen, J.D., and Fu, C.C. 
2001. Abnormal glucose tolerance in transfusion-dependent beta-thalassemic patients. 
Diabetes Care 24:850-854. 
 
44. Abraham, D., Rogers, J., Gault, P., Kushner, J.P., and McClain, D.A. 2006. 
Increased insulin secretory capacity but decreased insulin sensitivity after correction of 
iron overload by phlebotomy in hereditary haemochromatosis. Diabetologia 49:2546-
2551. 
 
45. Cooksey, R.C., Jouihan, H.A., Ajioka, R.S., Hazel, M.W., Jones, D.L., Kushner, 
J.P., and McClain, D.A. 2004. Oxidative stress, beta-cell apoptosis, and decreased 
insulin secretory capacity in mouse models of hemochromatosis. Endocrinology 
145:5305-5312. 
 
46. Cooksey, R.C., Jones, D., Gabrielsen, S., Huang, J., Simcox, J.A., Luo, B., 
Soesanto, Y., Rienhoff, H., Abel, E.D., and McClain, D.A. 2010. Dietary iron restriction 
or iron chelation protects from diabetes and loss of beta-cell function in the obese 
(ob/ob lep-/-) mouse. Am J Physiol Endocrinol Metab 298:E1236-1243. 
 
47. Ramey, G., Faye, A., Durel, B., Viollet, B., and Vaulont, S. 2007. Iron overload 
in Hepc1(-/-) mice is not impairing glucose homeostasis. FEBS Lett 581:1053-1057. 
 
48. Huang, F.W., Pinkus, J.L., Pinkus, G.S., Fleming, M.D., and Andrews, N.C. 
2005. A mouse model of juvenile hemochromatosis. J Clin Invest 115:2187-2191. 
 
49. Panel, N. 2002. Third Report of the National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421. 
 
50. Grundy, S.M., Hansen, B., Smith, S.C., Jr., Cleeman, J.I., Kahn, R.A., American 
Heart, A., National Heart, L., Blood, I., and American Diabetes, A. 2004. Clinical 
management of metabolic syndrome: report of the American Heart Association/National 
Heart, Lung, and Blood Institute/American Diabetes Association conference on 
scientific issues related to management. Circulation 109:551-556. 
 
51. Levin, N., Nelson, C., Gurney, A., Vandlen, R., and de Sauvage, F. 1996. 
Decreased food intake does not completely account for adiposity reduction after ob 






   
52. Seltzer, C.C., and Mayer, J. 1963. Serum Iron and Iron-Binding Capacity in 
Adolescents. Ii. Comparison of Obese and Nonobese Subjects. Am J Clin Nutr 13:354-
361. 
 
53. Nead, K.G., Halterman, J.S., Kaczorowski, J.M., Auinger, P., and Weitzman, M. 
2004. Overweight children and adolescents: a risk group for iron deficiency. Pediatrics 
114:104-108. 
 
54. Gillum, R.F. 2001. Association of serum ferritin and indices of body fat 
distribution and obesity in Mexican American men--the Third National Health and 
Nutrition Examination Survey. Int J Obes Relat Metab Disord 25:639-645. 
 
55. Aeberli, I., Hurrell, R.F., and Zimmermann, M.B. 2009. Overweight children have 
higher circulating hepcidin concentrations and lower iron status but have dietary iron 
intakes and bioavailability comparable with normal weight children. Int J Obes (Lond) 
33:1111-1117. 
56. Pelleymounter, M.A., Cullen, M.J., Baker, M.B., Hecht, R., Winters, D., Boone, 
T., and Collins, F. 1995. Effects of the obese gene product on body weight regulation in 
ob/ob mice. Science 269:540-543. 
 
57. Zimmermann, M.B., Zeder, C., Muthayya, S., Winichagoon, P., Chaouki, N., 
Aeberli, I., and Hurrell, R.F. 2008. Adiposity in women and children from transition 
countries predicts decreased iron absorption, iron deficiency and a reduced response to 
iron fortification. Int J Obes (Lond) 32:1098-1104. 
 
58. del Giudice, E.M., Santoro, N., Amato, A., Brienza, C., Calabro, P., Wiegerinck, 
E.T., Cirillo, G., Tartaglione, N., Grandone, A., Swinkels, D.W., et al. 2009. Hepcidin in 
obese children as a potential mediator of the association between obesity and iron 
deficiency. J Clin Endocrinol Metab 94:5102-5107. 
 
59. Amato, A., Santoro, N., Calabro, P., Grandone, A., Swinkels, D.W., Perrone, L., 
and del Giudice, E.M. 2010. Effect of body mass index reduction on serum hepcidin 
levels and iron status in obese children. Int J Obes (Lond) 34:1772-1774. 
 
60. McClung, J.P., Andersen, N.E., Tarr, T.N., Stahl, C.H., and Young, A.J. 2008. 
Physical activity prevents augmented body fat accretion in moderately iron-deficient 
rats. J Nutr 138:1293-1297. 
 
61. Huang, J., Gabrielsen, J.S., Cooksey, R.C., Luo, B., Boros, L.G., Jones, D.L., 
Jouihan, H.A., Soesanto, Y., Knecht, L., Hazel, M.W., et al. 2007. Increased glucose 
disposal and AMP-dependent kinase signaling in a mouse model of hemochromatosis. 
J Biol Chem 282:37501-37507. 
 
62. Huang, J., Jones, D., Luo, B., Sanderson, M., Soto, J., Abel, E.D., Cooksey, 
R.C., and McClain, D.A. 2011. Iron overload and diabetes risk: a shift from glucose to 
Fatty Acid oxidation and increased hepatic glucose production in a mouse model of 
hereditary hemochromatosis. Diabetes 60:80-87. 
 







   
64. Babitt, J.L., and Lin, H.Y. 2011. The molecular pathogenesis of hereditary 
hemochromatosis. Semin Liver Dis 31:280-292. 
 
65. Santos, P.C., Krieger, J.E., and Pereira, A.C. 2012. Molecular diagnostic and 
pathogenesis of hereditary hemochromatosis. Int J Mol Sci 13:1497-1511. 
 
66. Babitt, J.L., Huang, F.W., Wrighting, D.M., Xia, Y., Sidis, Y., Samad, T.A., 
Campagna, J.A., Chung, R.T., Schneyer, A.L., Woolf, C.J., et al. 2006. Bone 
morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat 
Genet 38:531-539. 
 
67. Faust, I.M., Johnson, P.R., Stern, J.S., and Hirsch, J. 1978. Diet-induced 
adipocyte number increase in adult rats: a new model of obesity. Am J Physiol 
235:E279-286. 
 
68. Jo, J., Gavrilova, O., Pack, S., Jou, W., Mullen, S., Sumner, A.E., Cushman, 
S.W., and Periwal, V. 2009. Hypertrophy and/or Hyperplasia: Dynamics of Adipose 
Tissue Growth. PLoS Comput Biol 5:e1000324. 
 
69. Zhou, Y.T., Wang, Z.W., Higa, M., Newgard, C.B., and Unger, R.H. 1999. 
Reversing adipocyte differentiation: implications for treatment of obesity. Proc Natl Acad 
Sci U S A 96:2391-2395. 
 
70. Wang, M.Y., Orci, L., Ravazzola, M., and Unger, R.H. 2005. Fat storage in 
adipocytes requires inactivation of leptin's paracrine activity: implications for treatment 
of human obesity. Proc Natl Acad Sci U S A 102:18011-18016. 
 
71. Buettner, C., Muse, E.D., Cheng, A., Chen, L., Scherer, T., Pocai, A., Su, K., 
Cheng, B., Li, X., Harvey-White, J., et al. 2008. Leptin controls adipose tissue 
lipogenesis via central, STAT3-independent mechanisms. Nat Med 14:667-675. 
 
72. Ahima, R.S., and Flier, J.S. 2000. Leptin. Annu Rev Physiol 62:413-437. 
 
73. Clement, K., Vaisse, C., Lahlou, N., Cabrol, S., Pelloux, V., Cassuto, D., 
Gourmelen, M., Dina, C., Chambaz, J., Lacorte, J.M., et al. 1998. A mutation in the 
human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392:398-
401. 
 
74. Banks, W.A., and Farrell, C.L. 2003. Impaired transport of leptin across the 
blood-brain barrier in obesity is acquired and reversible. Am J Physiol Endocrinol Metab 
285:E10-15. 
 
75. Banks, W.A., DiPalma, C.R., and Farrell, C.L. 1999. Impaired transport of leptin 
across the blood-brain barrier in obesity. Peptides 20:1341-1345. 
 
76. Munzberg, H., and Myers, M.G., Jr. 2005. Molecular and anatomical 
determinants of central leptin resistance. Nat Neurosci 8:566-570. 
 
77. Loh, K., Fukushima, A., Zhang, X., Galic, S., Briggs, D., Enriori, P.J., Simonds, 
S., Wiede, F., Reichenbach, A., Hauser, C., et al. 2011. Elevated hypothalamic TCPTP 





   
78. Myers, M.G., Jr., Leibel, R.L., Seeley, R.J., and Schwartz, M.W. 2010. Obesity 
and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab 
21:643-651. 
 
79. Rico, L., Del Rio, M., Bravo, A., Ramirez, A., Jorcano, J.L., Page, M.A., and 
Larcher, F. 2005. Targeted overexpression of leptin to keratinocytes in transgenic mice 
results in lack of skin phenotype but induction of early leptin resistance. Endocrinology 
146:4167-4176. 
 
80. Levin, B.E., Dunn-Meynell, A.A., and Banks, W.A. 2004. Obesity-prone rats 
have normal blood-brain barrier transport but defective central leptin signaling before 
obesity onset. Am J Physiol Regul Integr Comp Physiol 286:R143-150. 
 
81. Gabrielsen, J.S., Gao, Y., Simcox, J.A., Huang, J., Thorup, D., Jones, D., 
Cooksey, R.C., Gabrielsen, D., Adams, T.D., Hunt, S.C., et al. 2012. Adipocyte iron 
regulates adiponectin and insulin sensitivity. J Clin Invest 122:3529-3540. 
 
82. Taylor, R.P., Geisler, T.S., Chambers, J.H., and McClain, D.A. 2009. Up-
regulation of O-GlcNAc transferase with glucose deprivation in HepG2 cells is mediated 
by decreased hexosamine pathway flux. J Biol Chem 284:3425-3432. 
 
83. Hu, P., Shimoji, S., and Hart, G.W. 2010. Site-specific interplay between O-
GlcNAcylation and phosphorylation in cellular regulation. FEBS Lett 584:2526-2538. 
 
84. Hart, G.W., Housley, M.P., and Slawson, C. 2007. Cycling of O-linked beta-N-
acetylglucosamine on nucleocytoplasmic proteins. Nature 446:1017-1022. 
 
85. Hart, G.W., and Akimoto, Y. 2009. The O-GlcNAc Modification. In Essentials of 
Glycobiology. A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. 
Bertozzi, G.W. Hart, and M.E. Etzler, editors. Cold Spring Harbor (NY). 
 
86. Weigert, C., Klopfer, K., Kausch, C., Brodbeck, K., Stumvoll, M., Haring, H.U., 
and Schleicher, E.D. 2003. Palmitate-induced activation of the hexosamine pathway in 
human myotubes: increased expression of glutamine:fructose-6-phosphate 
aminotransferase. Diabetes 52:650-656. 
 
87. Rexach, J.E., Clark, P.M., Mason, D.E., Neve, R.L., Peters, E.C., and Hsieh-
Wilson, L.C. 2012. Dynamic O-GlcNAc modification regulates CREB-mediated gene 
expression and memory formation. Nat Chem Biol 8:253-261. 
 
88. Ho, S.R., Wang, K., Whisenhunt, T.R., Huang, P., Zhu, X., Kudlow, J.E., and 
Paterson, A.J. 2010. O-GlcNAcylation enhances FOXO4 transcriptional regulation in 
response to stress. FEBS Lett 584:49-54. 
 
89. Wollaston-Hayden, E.E., Harris, R.B., Liu, B., Bridger, R., Xu, Y., and Wells, L. 
2014. Global O-GlcNAc Levels Modulate Transcription of the Adipocyte Secretome 
during Chronic Insulin Resistance. Front Endocrinol (Lausanne) 5:223. 
 
90. Issad, T., and Kuo, M. 2008. O-GlcNAc modification of transcription factors, 





   
91. Lunde, I.G., Aronsen, J.M., Kvaloy, H., Qvigstad, E., Sjaastad, I., Tonnessen, T., 
Christensen, G., Gronning-Wang, L.M., and Carlson, C.R. 2012. Cardiac O-GlcNAc 



















ADIPOCYTE IRON REGULATES ADIPONECTIN THROUGH  











 *Reprinted with permission by J. Scott Gabrielsen, Yan Gao, Judith A. Simcox, Jingyu 
Huang, David Thorup, Deborah Jones, Robert C. Cooksey, David Gabrielsen, Ted D. 
Adams, Steven C. Hunt, Paul N. Hopkins, William T. Cefalu, and Donald A. McClain, 
2012;122(10):3529-3540, from Journal of Clinical Investigation, American Society for 

































































   



















ADIPOCYTE IRON REGULATES LEPTIN AND FOOD INTAKE 






   
Abstract 
Dietary iron supplementation is associated with increased appetite. We 
therefore investigated the effect of iron on leptin, a hormone regulating food intake and 
energy homeostasis. Serum ferritin is negatively associated with serum leptin in a 
cohort of humans with metabolic syndrome. This correlation is recapitulated in mice fed 
a high iron diet. Loss of the iron exporter, ferroportin, in adipocyte resulted in iron 
loading and decreased leptin. Conversely, decreased levels of hepcidin in hereditary 
hemochromatosis result in increased adipocyte ferroportin expression, decreased 
adipocyte iron, and increased leptin. Treatment of 3T3-L1 adipocytes with iron 
decreased leptin mRNA in a dose-dependent manner. We found iron negatively 
regulated leptin transcription via cAMP-responsive element (CRE)-binding protein 
(CREB) activation. Two potential CREB-binding sites were identified in the mouse leptin 
promoter region. Mutation of both sites completely blocked the effect of iron on 
promoter activity. We also found enrichment of phosphor-CREB binding to those two 
sites by ChIP in 3T3-L1 adipocytes treated with iron. Consistent with the changes in 
leptin, dietary iron content was also directly related to food intake, independently of 
weight. These findings indicate that levels of dietary iron play an important role in 
regulation of appetite and metabolism through CREB-dependent modulation of leptin 
expression. 
Introduction 
Iron deficiency is the most common nutrient deficiency in the United States (1). 
Individuals with iron deficiency have appetite loss, while dietary iron supplementation is 
associated with growth and increased appetite in children (2, 3). The mechanism 
underlying these associations is poorly understood. Leptin, the protein product of the ob 
gene, is a hormone that is secreted primarily by adipose tissue and responsible for 
37 
  
   
regulating feeding behavior. It is also strongly and positively associated with BMI and 
total body fat. Individuals with iron deficiency also have a higher prevalence of obesity 
(4-8). Any direct association between leptin and iron would be difficult to discern given 
the findings above, because either high iron consumption or lower adiposity would 
result in decreased leptin. There are, however, suggestions for a direct relationship 
between iron and leptin. Patients with β thalassemia major, a condition usually 
accompanied by transfusional iron overload, fail to maintain adequate leptin production 
(9-11). Furthermore, the association between BMI and serum leptin levels is dampened 
or even abolished in these patients (12). Soluble transferrin receptor (sTfR), a clinical 
marker for total body iron stores, is negatively associated with serum leptin (13). 
Finallly, serum ferritin, an iron storage protein and marker of both tissue iron stores and 
inflammation, is significantly correlated with appetite score and food intake (14). They 
do not, however, demonstrate causality nor mechanism for any of the relationships. 
We therefore investigated the effect of iron on leptin. We demonstrate in 
humans that the association between serum ferritin and leptin is independent of 
inflammation and body fat mass, and that serum ferritin, even within its normal range, is 
among the best predictors of serum leptin. Studies in cell culture, mouse models, and 
humans demonstrate that iron plays a direct and causal role in determining leptin levels. 
Thus, the adipocyte responds to iron availability as well as macronutrient status to 
adjust expression of leptin, a major regulator of appetite, energy homeostasis, and 
metabolism. 
Results 
Human ferritin levels are inversely associated with serum leptin independently of 
inflammation and BMI. We examine the relationship of iron and leptin in a cohort of 76 
individuals with (n = 36) and without (n = 40) diabetes recruited for an independent 
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study of metabolic flexibility (15). Ferritin was measured as an indicator of tissue iron 
stores. Ferritin is also an acute phase response protein whose concentrations increase 
during inflammation and no longer reflect the level of iron stores. To mitigate the effects 
of inflammation and/or extreme iron overload and anemia, we restricted the analysis to 
individuals with normal serum ferritin (men, >30 ng/ml and <300 ng/ml; women, >15 
ng/ml and <200 ng/ml) (16, 17). Excluding 12 individuals outside this range, we found a 
significant negative association between ferritin and leptin (Figure 2.1A, r = -0.474, P = 
0.0002). Serum ferritin is also negatively associated with serum leptin when individuals 
with abnormal ferritin are included, although the association is somewhat weaker (r = -
0.409, P = 0.002, Supplementary data Figure 2.S1A). Correcting for potential covariates 
including an independent marker of inflammation (C-reactive protein, CRP), BMI, and 
diabetes status, had little effect on the ferritin-leptin association (Table 2.1). Serum iron 
was also significantly negatively correlated with leptin (r = 0.407, p=0.003, Figure 2.1B).   
Inclusion of gender in the analysis has little effect on the serum ferritin and leptin 
association (Table 2.1), and serum ferritin level is second only to BMI in predicting 
leptin (Table 2.1). Average ferritin values are significantly lower compared with that in 
men (average ferritin, 77.07 ± 12.38 ng/ml in women and 162.64 ± 17.89 ng/ml in men, 
P = 1.26 X 10^-4) (18),  and these lower ferritin levels are accompanied by higher leptin 
levels in women (22.98 ± 1.85 μg/ml vs. 9.41 ± 1.27 μg/ml in men, P = 7.84 X 10^-7), 
despite their BMI values being equivalent (31.56 ± 1.21 in women and 30.62 ± 1.29 in 
men). 
Dietary iron overload increases adipocyte iron and decreases leptin mRNA and 
serum protein levels in mice. Our previous studies have identified effects of iron on 
adiponectin and adipocyte metabolism (19, 20). To explore the regulation of adipocyte 
iron levels, we first measured the cytosolic iron in isolated adipocytes by inductively 
coupled plasma atomic emission spectroscopy (ICP-AES). We observed a 215% 
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increase of iron in adipocytes from mice fed a high iron diet (2000 mg/kg iron) 
compared with that in mice fed normal chow (low normal iron diet, 35 mg/kg iron) 
(Figure 2.2A, P<0.05). We also demonstrated that adipocyte iron levels respond to 
dietary iron content in wild-type C57BL6/J mice by measuring mRNA levels of the 
transferrin receptor (Tfrc). Tfrc mRNA contains iron response elements in its 3’ 
untranslated region (UTR) that result in decreased Tfrc mRNA levels as cellular iron 
levels increase (21). We observed a 50% decrease in Tfrc mRNA in adipose tissue 
from mice fed a high iron diet (2000 mg/kg iron) compared with that in mice fed the low 
normal iron chow (35 mg/kg iron) (Figure 2.2B, P < 0.05). Serum leptin decreased with 
dietary iron (linear regression, p=0.003, n = 36/group, Supplementary data Figure 
2.S3). Serum leptin levels were 42% lower in mice on the high iron diet (2000 mg/kg 
iron) compared to those on the low normal iron diet (35 mg/kg iron) (Figure 2.2C, P = 
0.0009). Intracellular leptin levels assayed by western blotting were 35% lower (Figure 
2.2D and 2.2E) and leptin mRNA levels in epididymal pads were 41% lower in iron 
overloaded mice (Figure 2.2F, P = 0.009), mirroring the changes in serum leptin levels. 
To further confirm the effect of iron on leptin, transgenic mice expressing the luciferase 
reporter gene under the control of leptin regulatory sequences were fed the low normal 
or high iron diets (35 mg/kg vs. 2000 mg/kg iron). Fluorescence after intraperitonal 
injection with D-luciferin was 15% lower in the mice on high iron, both after fasting (48 
h) or 6 h after refeeding (Figure 2.2G and 2.2H). 
Deletion of adipocyte ferroportin results in increased adipocyte iron levels, 
decreased serum leptin. Previously, we have generated mice lacking the gene 
encoding the iron export channel ferroportin (Fpn) in adipocytes. An Fpn1fl/fl mouse, 
provided by Nancy C. Andrews (Duke University, Durham, North Carolina, USA) (22), 
was crossed to a mouse expressing Cre recombinase under control of the ap2 
promoter to obtain the adipocyte-specific ferroportin knockout mice (aFpnKO) (23). 
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Ferroportin mRNA was undetectable in adipocytes purified by collagenase digestion 
from aFpnKO mice. Tfrc mRNA exhibited a decrease in isolated adipocytes of aFpnKO 
mice, indicating relative iron overloading compared to wide-type mice (19). The 
increased levels of adipocyte iron in the aFpnKO  mice resulted in a 49% decrease in 
levels of serum leptin (Figure 2.3A, P < 0.01). There was no change in body weight or 
body composition as analyzed by a Magnetic Resonance Imaging (MiniSpec, Bruker) 
(Figure 2.3B).  
Lower adipocyte iron is associated with higher serum leptin in hereditary 
hemochromatosis. If iron decreases leptin secretion, we would expect high leptin levels 
in models of decreased adipocyte iron. Hfe–/– mice are a model of human hereditary 
hemochromatosis (HH), a disease of genetic iron overload wherein the gene most 
commonly mutated in HH has been deleted. HFE protein is required for normal 
regulation of a master iron regulatory hormone, hepcidin, which reduces the iron export 
channel ferroportin (24, 25). HH or HFE deletion results in low hepcidin, increased 
ferroportin expression, and increased iron egress from cells that express ferroportin, 
such as duodenal enterocytes.  Adipocytes also express ferroportin as demonstrated 
previously by us, and are therefore paradoxically low iron level in this disease of overall 
iron overload (19). HFE-/- mice therefore have less iron in adipocytes, and we 
determined that this results in higher serum leptin compared to littermate WT mice 
(Figure 2.3C).  
Iron decreases leptin transcription and activates CREB. To demonstrate that the 
decreased leptin mRNA levels are due to decreased transcription and that iron 
regulates leptin directly, we examined the effects of iron on leptin in a cell culture 
model. We observed a decrease of leptin after treatment with ferric ammonium citrate 
(FAC) in primary mouse adipocytes isolated from inguinal white adipose tissue (iWAT) 
and progenitor cells isolated by fluorescence-activated cell sorting (FACS) and 
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differentiated in vitro (Figure 2.4A and Supplementary data Figure 2.S4). 3T3-L1 
adipocytes differentiated with isobutylmethylxanthine/dexamethasone/insulin express 
very little leptin transcript, but when differentiated in the presence of a PPARγ agonist, 
ciglitazone, the adipocytes have been shown to exhibit a 5-fold increase in leptin mRNA 
and maintain insulin sensitivity and their differentiated phenotype (26).  Using this cell 
culture model, treatment of 3T3-L1 adipocytes with FAC decreased intracellular leptin 
protein levels measured by western blotting (Figure 2.4B and 2.4C). Secreted leptin in 
the medium decreased 36% with iron treatment (Figure 2.4D, P <0.05), which was 
reversed by an iron chelator, deferoxamine (DFO). Similarly, leptin mRNA levels also 
decreased 48% with iron treatment (P <0.05) and DFO treatment abolished the iron-
induced decrease of leptin mRNA (Figure 2.4E). The decrease in leptin by iron 
treatment was dose-dependent (Figure 2.4F, r = 0.668, P < 0.01). The levels of iron 
used in treating the cultured adipocytes have been shown to cause a parallel dose-
dependent decrease in the expression of Tfrc and iron level measured by ICP-AES 
(19), indicating that the resulting intracellular iron levels are in a physiologically sensed 
range. Iron can regulate mRNA levels posttranscriptionally by iron-response elements 
(IRE) and iron-responsive proteins (IRP). Binding of IRP to IRE in the 3’-UTR of mRNA 
typically increases mRNA stability, while binding of IRP to the 5’-UTR typically 
decreases translation. Binding of free iron to IRPs causes their dissociation from the 
mRNA and either enhanced mRNA degradation (3’-IRE) or enhanced translation (5’-
IRE). Leptin mRNA possesses a 59bp 5’-UTR and 2.7kb 3’-UTR. We transfected 3T3-
L1 adipocytes with constructs containing luciferase with each or both UTRs and found 
no effect of iron on luciferase activity, indicating leptin is not an IRE-IRP targeted gene 
(Supplementary data Figure 2.S5). Iron also did not decrease the half-life of the 
endogenous mRNA measured after actinomycin D treatment of cells (data not shown).  
We next constructed two luciferase reporter plasmids with the proximal 5,986bp 
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and 764bp of the murine leptin promoter. We first measured luciferase activity driven by 
the proximal 764 bp of the murine leptin promoter, a region that contains sites known to 
regulate leptin transcription, including CCAAT/enhancer binding protein (C/EBP), 
specificity protein 1 (SP1), and the hypoxia response element (HRE). Iron did not 
decrease the activity of this proximal promoter (Supplementary data Figure 2.S6). 
Luciferase activity driven by 5,986bp leptin promoter, however, decreased 33% after 
FAC treatment of the cells (Figure 2.5A). We found this region, as well as the human 
leptin promoter (27), contains potential cAMP response elements (CRE) as predicted 
from the transcriptional database of GenBank. We therefore investigated the effect of 
iron on CRE binding protein (CREB) activation. FAC treatment resulted in increased 
phosphorylation of CREB and slightly decreased total protein levels (Figure 2.5B and 
2.5C). Consistent with the increased phosphorylation of CREB, we also observed 
(Supplemental Figure 2.S7A). Increased CREB phosphorylation in iron-treated cells 
occurred independently of two of its known activators, cAMP and calcium, with FAC 
treatment actually decreasing both of them (Supplementary data Figure 2.S8). A 
membrane-permeable cAMP analogue (8-Br-cAMP) activates a known CREB kinase, 
cyclic AMP-dependent protein kinase. Treatment of 3T3-L1 adipocytes with 8Br-cAMP 
or the adenylyl cyclase activator forskolin decreased luciferase activity and abolished 
iron’s effect on expression of the 5,986bp luciferase construct (Figure 2.5D and 2.5E). 
8Br-cAMP treatment also decreased leptin transcript levels (Supplementary data Figure 
2.S7B), but did not affect iron metabolism in terms of Tfrc expression (Supplementary 
data Figure 2.S7C). We generated 3T3-L1 cells stably expressing a dominant negative 
CREB inhibitor, ACREB, a synthetic polypeptide that heterodimerizes with and disrupts 
binding of CREB1, CREM, and ATF1, but not unrelated bZIP proteins to DNA (28). In 
cells expressing ACREB, iron lost its effect on decreasing the 5,986bp promoter 
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luciferase activity, confirming that functional CREB sites confer iron-responsiveness to 
the promoter (Figure 2.5E).  
Iron increases CREB occupancy of the leptin promoter. We mutated three 
potential CREB sites in each of two 5,986bp plasmids (plasmids 425 and 533, 
Supplementary data Figure 2.S9A). Iron lost its ability to decrease luciferase activity in 
3T3-L1 adipocytes stably expressing plasmid 533 but not in cells expressing wild type 
or 425 plasmids (Figure 2.6A). Plasmid 533 contains two potential CRE sites and one 
typical AP-1: CRE-like site, from -2590 bp to -2583 bp (CRE-1, CTACTTCA), from -
2080 bp to -2073bp (CRE-2, CTATGTCA) and from -877 to -883 (AP-1: CRE-like, 
TTAGTCA) (Supplementary data Figure 2.S9B). AP-1, and CRE proteins recognize a 
similar DNA sequence and there is evidence that the fos/jun (components of AP-1) 
complex and CREB families are able to dimerize and bind to AP-1/CRE-like sequences, 
allowing crosstalk between the two signaling systems (29-31), and such degenerate 
CRE sites can be functional, as shown in other systems (32-34). We performed EMSA 
on the CRE-1, CRE-2, and AP-1/CRE-like sites. Three oligonucleotide probes 
containing the CRE-1, CRE-2, and AP-1/CRE-like sequences were synthesized and 
biotinylated. Both biotin-labeled CRE-1 and CRE-2 formed a complex with nuclear 
extracts (Figure 2.6B). Coincubation with a 200-fold excess of a nonbiotin-labeled CRE-
1 or CRE-2 oligonucleotide effectively abolished complex formation. A mutated 
oligonucleotide in which the potential CRE-1 binding sequence (CTACTTCA) was 
mutated to mCRE-1 (CTAAATCA) failed to compete for binding with the biotin-labeled 
CRE-1 probe (Figure 2.6B). Similarly, mutation of the potential CRE-2 site (TATGTCA) 
to mCRE-2 (TATGTCA) resulted in failure to compete for the binding of biotin-CRE-2 to 
nuclear protein (Figure 2.6C). We did not observe any band shifts of biotin-labeled AP1 
oligonucleotides after incubation with 3T3-L1 nuclear extracts (Supplementary data 
Figure 2.S10). These findings indicate that the CRE-1 and -2 sequences in the leptin 
44 
  
   
promoter are functional binding sites. We next measured CREB occupancy at those two 
potential CRE sites using ChIP. As predicted by CREB phosphorylation status, cells 
treated with iron exhibited a 3- to 4-fold increase in occupancy by pCREB at the CRE1 
and CRE2 sites (P < 0.01, Figure 2.6D).  
Iron-induced decrease of leptin is associated with increased food intake. To 
demonstrate that iron-induced changes in leptin are physiologically significant, we 
studied the effects of chows with different dietary iron content on serum leptin and food 
intake in mice. We fed C57BL6/J male mice very high (20 g/kg carbonyl iron), high 
(2000 mg/kg), high normal (500 mg/kg), low normal  (35 mg/kg) or low (4 mg/kg) iron 
diets for 2 months. The 35 mg/kg diets are derived from TestDiet® AIN-93G 
recommended by the American Institute of Nutrition. The 500 mg/kg iron diet is 
representative of standardized diets in animal facilities which range from 200 to 500 
mg/kg iron.  The 2000 mg/kg iron diet results in a modest increase of liver iron (2-fold) 
which is within the 4-fold range seen in normal humans (35). The highest iron diet is 2% 
carbonyl iron (20 g/kg iron diet), which increases plasma iron by two-fold after 24 weeks 
on diet (36). Mice were studied in metabolic chambers with monitoring of food intake 
after 9 to 12 weeks on the diets. We observed a positive correlation of dietary iron 
levels and food consumption (Figure 2.7A, r = 0.5914, P < 0.001). Mice on the high iron 
diet (2000 mg/kg) tend to eat more during each 15 min interval in the chamber during 3 
days (Figure 2.7B, upper panel, P =0.0084) and accumulated food intake is higher in 
high iron diet (2000 mg/kg) compared to low iron diet (4 mg/kg iron) (Figure 2.7B, lower 
panel, P = 0.0002). Body weights did not change with different dietary iron after 9 
weeks on diet (low iron, 28.88 ± 0.31 g; low normal chow, 29.55 ± 0.33 g; high normal 
iron, 28.26 ± 0.37 g; high iron, 28.76 ± 0.30 g, linear regression, P = 0.104, n = 
36/group, supplementary data 2.S11). To demonstrate that the change of feeding 
behavior under different levels of dietary iron is mediated through changes in leptin 
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levels, we fed the same diets to ob/ob mice, where the leptin gene is mutated and 
nonfunctional. In ob/ob mice, the association of dietary iron level with food intake is 
abolished (Figure 2.7C). Similarly, no difference in food intake was apparent comparing 
mice on the high iron diet (2000 mg/kg) to those on the low iron diet (4 mg/kg iron) in 
lively food intake and accumulated food intake (Figure 2.7D), and in bar-graphed data 
(Figure 2.7E) in ob/ob mice. 
Discussion  
Iron is an essential constituent of many macromolecules involved in cell 
metabolism, and is required for survival and proliferation. At the same time, iron can act 
as a potent and potentially dangerous oxidant. Iron levels are therefore highly regulated 
at the levels of uptake, storage, and recycling in the whole organism as well as 
individual tissues and cells. A typical adult has total body iron stores of ~1-3 g. A 
balance between dietary uptake and tissue loss is usually maintained in healthy 
humans wherein 1 to 3 mg daily losses through bleeding and sloughing of cells from 
skin and mucosal surfaces is balanced by gastrointestinal uptake (37, 38). However, 
there is no defined physiological means of active iron excretion, so the levels of tissue 
iron can increase over time with dietary excess, such that normal levels of serum 
ferritin, a marker of tissue iron stores in otherwise healthy individuals, vary 15- to 20-
fold. We have previously hypothesized that the central role of iron in metabolism 
dictates that its availability should be reflected in the metabolic state of the organism, 
and that cells that regulate metabolism such as adipocytes therefore need to sense not 
only the macronutrient status of the organism but also the availability of iron to support 
fuel oxidation. This hypothesis is supported by the regulation of adiponectin by iron 
(19). Recent studies have also noted an association between serum ferritin, soluble 
transferrin receptor, and leptin, the adipocyte-specific satiety hormone (13, 14). In this 
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paper, we have verified that serum ferritin levels, reflecting tissue iron stores, are 
among the best predictors of serum leptin under physiological conditions. We have 
demonstrated this in humans, in cultured cells, and by manipulation of iron stores and 
adipocyte iron levels in rodents. More importantly, the relationship is causal, reflecting 
regulation of leptin transcription by iron.  Leptin is causally linked to feeding behavior 
(39), and, consistent with this, the changes in leptin in response to iron are 
accompanied by changes in food intake.  
The regulation of leptin by iron is operative across physiologic and 
pathophysiologic iron levels. The current report demonstrates regulation across the 
range of normal human serum ferritin values. BMI is well known to be positively 
correlated with serum leptin (40), and consistent with this, we found serum leptin in the 
obese subjects (upper 25th percentile BMI) to be 3.7-fold higher than that in the lean 
subjects (lower 25th percentile BMI) (Supplemental data Figure 2.S2A). At the same 
time, we found serum leptin in the low iron subjects (lower 25th percentile ferritin) is 3.2-
fold higher than that in the high iron subjects (higher 25th percentile ferritin) 
(Supplemental data Figure 2.S2B), indicating ferritin is also a good clinical predictor of 
leptin. Our results suggest that this may be a direct result of adipocyte iron loading even 
within the physiologic range. In the mouse studies, as we have previously reported, the 
low normal (35 mg/kg) and high normal (500 mg/kg) iron diets represent the range of 
iron content seen in normal chows, and the high iron diet (2000 mg/kg) does not cause 
overt iron pathology and results in increases in hepatic iron within the ranges seen in 
normal humans (41). Likewise, in the cell culture models, addition of iron to cells results 
in modulation of the transferrin receptor in a manner that mirrors normal iron 
physiology. Thus, we think the ranges of iron represented in these model systems 
reflect the variation seen in normal humans, and leptin is regulated throughout these 
ranges of iron.  
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Although we did not study humans with overt iron deficiency or overload, 
previous reports are consistent with the current results and demonstrate that the 
association of leptin and iron is also maintained in pathophysiologic states. Leptin levels 
are lower (10, 11, 13) and the normal positive relationship between BMI and leptin is 
lost in males suffering from thalassemia major, a condition in which transfusional iron 
overload develops (12). Leptin levels remain low in those thalassemic patients even at 
high BMI. At the other end of the spectrum, mice on the low iron diet (4 mg/kg) have low 
leptin. Although these mice maintain normal blood hemoglobin concentrations and are 
not overtly iron deficient, their hemoglobin concentrations are lower than animals on the 
higher iron diets. Consistent with this observation, dietary iron supplementation in iron-
deficient children results in increased growth and appetite (2). The normal association 
between leptin and body fat is also lost in the elderly, who are more likely to be 
effectively iron-deficient (16, 42). Overall, these mouse and culture models accurately 
reflect not only the broad range of “normal” physiology but pathologic human tissue iron 
levels as well.  
Obesity and iron deficiency are two common nutritional and health problems in 
the world and major cofactors in many other diseases (43, 44). Given this wide range of 
health implications, it is urgent to develop new and effective strategies in controlling 
obesity and find potential targets for weight control. Several studies have shown a 
greater prevalence of iron deficiency in overweight and obese people than normal-
weight ones (4, 5, 7, 45, 46). Analysis of public-use data files from the continuous 
National Health and Nutrition Examination Survey (NHANES) (1999-2006) indicate 
there is a negative relationship between levels of  blood iron content and individual BMI 
after controlling for other individual characteristics (47). Consistent with this, rats on an 
iron-deficient diet gain more fat mass than paired mice fed an iron-replete diet (48). 
However, the etiology of iron deficiency-associated obesity remains unknown. Several 
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hypotheses have been put forth to explain the occurrence of obesity in iron deficiency. 
Some have suggested that decreased iron is a consequence, not a cause of obesity, 
related to: (i) decreased iron intake associated with obesogenic diets or lifestyles; (ii) 
impairment of intestinal iron absorption and a reduced response to iron fortification in 
obesity (49); (iii) reduced iron release from iron stored cells and iron bioavailability 
because of obesity-associated inflammation that results in high levels of hepcidin, a 
protein that decreases ferroportin and iron release into the systemic circulation (50, 51). 
However, our current data suggest that another factor in the obesity associated with 
iron deficiency may be increased leptin and the resultant leptin resistance (45, 52). 
Additional mechanisms include changes in metabolism induced by iron. Previous 
results from our laboratory, for example, demonstrate that muscle from mice on a low 
iron diet exhibits increased fatty acid synthesis but decreased lipolysis and fatty acid 
oxidation (53). Conversely, iron overloaded mice change fuel usage from glucose to 
fatty acid oxidation in the muscle (54). All of these data demonstrate the importance of 
iron stores in determining the metabolic state of the organism, and suggest that iron 
sufficiency may aid in the prevention or treatment of obesity. At the same time, 
however, higher levels of iron, even within the “normal” range, may predispose to other 
metabolic abnormalities such as diabetes (41), metabolic syndrome, and nonalcoholic 
steatohepatitis (55).  Thus, optimal tissue iron levels may represent a significantly 
narrower range than that seen in the population as a whole. 
The molecular mechanism for the regulation of leptin by iron includes 
phosphorylation of CREB. Besides iron, CREB is another well-known factor that can 
change fuel utilizaiton from glucose to fat burning in mammals under fasting. Leptin is 
responsive to nutritional status, and fasting leads to a gradual decline in leptin (56, 57). 
CREB activation under fasting may play a role in diminishing leptin expression, and the 
cellular mechanism that causes leptin to fall with iron may be similar to that seen with 
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fasting. Fasting evokes a number of responses, including an increase of glucagon, a 
known activator of CREB (58). Thus, CREB may play a role in connecting not only iron 
but also macronutrient status to leptin. Prior to the current study, there was limited 
evidence for the regulation of leptin by CREB. It has been reported that activation of 
CREB during the differentiation process suppresses leptin secretion and expression in 
mesenchymal stem cell (59), and bioinformatics analysis indicates there are two 
potential CRE sites in the human ob promoter, but no study of their function has been 
reported (27). Interestingly, we have found that another nutrient-sensing pathway, the 
hexosamine biosynthesis pathway (HBP), which is also known to play a crucial role in 
regulation of CREB (60) and has been reported to regulate leptin expression (61), also 
contributes to iron-induced changes in leptin expression. Namely, increased 
phosphorylation of CREB is associated with a decrease of O-GlcNAcylation of CREB, 
and activation of the HBP by glucosamine overcomes the iron-induced inhibition of 
leptin (data not shown, manuscript in preparation). Thus, reciprocal interplay of 
“starvation” (CREB) and “overfeeding” (HBP) pathways modulate leptin expression in 
an iron-responsive manner. These observations further underline the close relationship 
of iron levels with overall nutritional status and metabolic regulation. 
In sum, the current results demonstrate that adipocytes serve to integrate not 
only the macronutrient status, but also the iron status of the organism to modulate 
metabolism, appetite, and energy homeostasis. Presumably, this would help maintain 
food-seeking behavior in an iron-rich environment that would support high rates of 
oxidative metabolism, energy production, growth, and reproduction. 
Methods 
Experimental animals. Dietary iron manipulations were accomplished with diets 
containing 60% carbohydrate, 17.7% protein, and 7.2% fat by weight, and either 4 
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mg/kg (TD. 10210), 35 mg/kg (TD. 10211), 500 mg/kg (TD. 10212), 2000 mg/kg (TD. 
10214), or 20 g/kg carbonyl iron (TD. 10213) (Harlan Teklad) for a period of 2 months 
before phenotyping. Wild-type mice were of the C57BL6/J strain. In addition, mice with 
targeted deletion of the Hfe gene were studied after being bred onto either the 
129/SvEvTac or C57BL6/J genetic backgrounds for at least 5 generations (62). Mice 
with adipocyte-specific deletion of the ferroportin gene were generated by breeding 
mice with LoxP sites flanking exon 6 and 7 of the ferroportin gene (22) (generously 
provided by Nancy C. Andrews, Duke University), with C57BL6/J mice containing an 
ap2-promoter-driven Cre recombinase (The Jackson Laboratory). Age- and sex-
matched WT littermates were used as controls. Body composition analysis was 
performed using a nuclear magnetic resonance system (Minispec LF-50 BCA Analyzer, 
Bruker). Transgenic mice expressing the luciferase reporter gene under the control of 
leptin regulatory sequences were generously provided by Dr. Jeffry M. Friedman (63). 
Human subjects. The subjects were part of a larger study and were described 
previously (15), and their samples were deidentified for this study. Diabetes status was 
confirmed by oral glucose tolerance testing (OGTT). Diabetic subjects were on diet 
therapy only, with fasting plasma glucose between 125 mg/dl and 175 mg/dl. All sera 
were obtained after a 12-hour overnight fast.  
Reagents and assays. Reagents were purchased from Sigma-Aldrich unless 
otherwise noted. Serum leptin levels were measured by ELISA kit (Millipore). Serum 
ferritin and iron were measured by ARUP laboratories (Salt Lake City, UT).  
In vivo imaging. In vivo imaging of leptin/luciferase transgenic animals was 
performed using the Xenogen IVIS Lumina II imaging system (Caliper). Because of the 
heterogeneity in the weights of the transgenic mice and the effect of weight on leptin, 
firefly levels were determined only in weight-matched mice. Isoflurane-anesthetized 
animals were injected intraperitonally with luciferin (300 μl of 15 mg/ml in PBS). The 
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animals were imaged in an imaging chamber 15 min after injection and the photon 
image was analyzed by Living Image 3.0 software (Xenogen) (63). 
3T3-L1 adipocyte culture and differentiation. 3T3-L1 adipocytes (ATCC) were 
maintained in high-glucose DMEM (HG-DMEM) supplemented with 10% bovine calf 
serum (BCS, Hyclone) and penicillin/streptomycin (Invitrogen). For differentiation (64), 
cells were incubated in HG-DMEM with 10% BCS for 48 h after confluence. Cells were 
then cultured in differentiation medium I (HG-DMEM, 10% FBS, 1 μg/ml insulin, 0.25 
μg/ml dexamethasone, 0.5 mM IBMX, 4μM ciglitazone) for 4 days, followed by 
differentiation medium II (HG-DMEM, 10% FBS, 1 μg/ml insulin) for 48 h. Prior to 
experiments, cells were cultured overnight in DMEM (Invitrogen) with 0.5% BSA. All 
experiments were performed in MEM-α medium, which is iron-free, supplemented with 
10% FBS and FAC as indicated. 
Plasmids, nucleofection, and luciferase assay. The ~6kb (5,986bp) and 764bp 
5’-flanking region of the murine leptin promoters were amplified with BglII-overhung or 
HindIII-overhung primers from genomic epididymal fat pad DNA and inserted into the 
pGL4.14 vector (Promega). Site-specific mutagenesis studies were carried out using 
QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent Technologies). 
Plasmids were nucleofected into undifferentiated 3T3-L1 preadipocytes using an 
Amaxa Nucleofector with Kit V (Lonza) and an electroperator (Nucleofector II AAD-
1001N, device no. 400414; Amaxa Biosystems, Cologne, Germany). After overnight 
incubation, positively transfected cells were selected by hygromycin. After two weeks’ 
selection, pools of cells were differentiated and also used to select clonal cell lines. 
Luciferase activity was quantified using the Luciferase Reporter Assay System 
(Promega) and a 96-well plate luminometer. Luciferase levels of specific genes were 
normalized to protein levels.  
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Isolation of primary adipocytes. Subcutaneous and epididymal fat pads were 
removed from male mice, and incubated in HBSS with 1% BSA and 1.5 mg/ml 
collagenase, type I, for 45 min at 37°C, rotating at 180 rpm. Adipocytes were filtered 
through 100-μm nylon mesh and rinsed with HBSS-1% BSA. Following centrifugation at 
880rpm, the fat cake was transferred to a clean tube, rinsed, and centrifuged. Isolated 
adipocytes were either used immediately or flash frozen in liquid nitrogen.  
Labeling, analysis, and sorting of adipose progenitor cells. Subcutaneous and 
epididymal adipose tissue was excised and the stromal vascular fraction (SVF) isolated 
as described (65). The SVF was resuspended in ice-cold HBSS with 10% FBS for 
labeling. Antibody incubations were performed on ice for 20 min. Cells were washed 
and resuspended in HBSS for sorting. Samples were sorted on a BD FACSAria cell 
sorter and analyzed on a BD LSRII (BD Biosciences) flow cytometer, each equipped 
with BD FACSDiva Software. For sorting, the cells were separated on the basis of the 
cell-surface markers indicated in the literature (66). 
Quantification of transcripts. Quantitative RT-PCR was performed as described 
previously (53). Briefly, mRNA was extracted from primary or 3T3-L1 adipocytes or fat 
pad using TRIzol (Invitrogen), purified using an RNeasy column (QIAgen), and 
synthesized into cDNA using a First-Strand cDNA Synthesis Kit (Invitrogen). The fat 
cake in TRIzol was cleared by transferring the infranatant to a clean tube using a glass 
syringe before extraction. Real-time PCR was performed with a QuantStudio real-time 
PCR systems (Applied Biosystems). cDNA products were quantified using the relative 
standard curve method. mRNA levels of specific genes were normalized to cyclophilin A 
or RPL13A. 
Antibodies. Antibodies used included pCREB (Ser 133) (87G3) and CREB 
(86B10) from Cell signaling Inc., ob (A20, sc842) from Santa Cruz Inc., and α-tubulin 
(T9026) from Sigma-Aldrich.  
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EMSA. Oligonucleotides were end labeled with biotin. Differentiated 3T3-L1 
adipocyte nuclear extracts were prepared using a nuclear extraction kit (Abcam 
ab113474). The binding reaction was done according to the LightShift 
Chemiluminescent kit manual with some modification (Thermo Scientific, Cat#20148). 
Briefly, nuclear extract was added to binding buffer containing 5 nM MgCl2, 0.05% NP-
40, 50 ng/uL poly(dI-dC), and 2.5% glycerol and incubated at room temperature for 10 
min add biotinylated oligonucleotide probe and incubated 25 min at room temperature. 
Protein-DNA complexes were resolved on 5% nondenaturing polyacrylamide gels and 
visualized by chemiluminescent nucleic acid detection module (Thermo Scientific, Cat# 
89880). For DNA competition EMSA, nonbiotinylated wild-type or mutant 
oligonucleotides were added first.  
ChIP. ChIP studies were performed as described with minor modification (67). 
Chromatin was extracted from 3T3-L1 adipocytes on day 10 to 13 after differentiation 
using the SimpleChIP kit (Cell signaling #9002) according to the manufacturer’s 
instructions. Briefly, cells were treated with 100 μg/mL of FAC for 24 h prior to 
crosslinking for 10 min with 1% formaldehyde. Cells were then lysed by micrococcal 
nuclease and sonicated three times for 20 s using a sonic dismembrator (Fisher 
Scientific). pCREB was then immunoprecipitated from precleared lysates with Protein 
A/Salmon sperm DNA agarose beads (Millipore). DNA was released from protein-DNA 
complexes by proteinase K digestion, and then subjected to quantitative real-time PCR 
using a power SYBR green kit (Applied Biosystem). The following primers, Fwd-5’- 
GCA CGA TGT AAC CAC GAA TG -3’ and Rev-5’- ACG TCC ATT CAG CAA AAA CC -
3’, were used to amplify the CRE1 site. Fwd-5’- GGC GAA AGG CAA ACA TAA GA-3’ 
and Rev-5’- TTC CCG CTC TGA CAT TCT TT-3’ primers were used to amplify the 
CRE2 site. ChIP-qPCR data were normalized for amount of chromatin by input samples 
and normal IgG samples.  
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Food intake measurement. Food intake was measured over a 3-day period with 
the Comprehensive Laboratory Animal Monitoring System (CLAMS; Columbus 
Instruments, Columbus, OH) using a four-chamber open-circuit system. Animals were 
acclimatized to the chambers overnight prior to data collection and maintained at 24°C 
under a 12:12-h light-dark cycle. Mice were housed individually with food and water 
freely available. Four mice were measured simultaneously. Food consumption was 
monitored by electronic scale for each mouse, and each cage was sampled for 1.5 min 
at 15 min intervals. Accumulated food intake was the sum of all acquired points.  
Statistics. Descriptive statistics in the text and figures are represented as 
average ± SEM. The Pearson’s correlation coefficient was calculated to test for 
correlation between 2 parameters. Multivariate logistic regression analysis using 
STATA was sequentially performed to investigate the role of CRP, BMI, diabetes, and 
gender on the ferritin-leptin association. An unpaired 2-tailed Student’s t test was used 
to determine significance between controls and individual experimental groups. A 
paired 2-tailed Student’s t test was used to determine significance between controls and 
individual experimental groups in leptin-luciferase mice.  One-way ANOVA was used to 
compare series of data. Wilcoxon signed-rank test was applied to compare real-time 
feeding behavior and accumulated food intake in different mouse groups in the 
metabolic chamber. P < 0.05 was considered significant for all tests.  
Study approval. Animal studies were approved by the Institutional Animal Care 
and Use Committee of the University of Utah, under IACUC approval A3031-01. The 
human studies were approved by the IRB of the University of Utah, protocols 0880 and 
20094. Studies were also reviewed and approved by the Advisory Committee to the 
Clinical Services Core (CSC) of the Center for Clinical and Translational Science. 
Additional previously unpublished data were from human studies completed at the 
Pennington Biomedical Research Center and at the University of Utah. Both studies 
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were approved by the IRBs of the respective institutions, as previously published (15, 
68). 
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Figure 2.1 Serum ferritin and iron levels are inversely associated with serum leptin 
levels. (A) Serum leptin and ferritin levels were measured and correlated in a cohort of 
subjects with normal ferritin (n=65). (B) Serum iron levels are inversely associated with 
serum leptin levels in a cohort of patients with type 2 diabetes as well as in obese 
subjects with metabolic syndrome (n=76). 
63 
  
   
Figure 2.2 Serum leptin and adipocyte leptin mRNA levels decrease with dietary iron 
overload. (A) Iron levels measured by inductively coupled plasma atomic emission 
spectroscopy (ICP-AES) in mice fed low normal (35mg/kg) and high (2000 mg/kg) iron 
diet (n=4 or 5 per group). (B) Tfrc mRNA levels quantified by RT-PCR and normalized 
to cyclophilin A in adipose tissue from mice fed different levels of dietary iron (n=36 per 
group). (C) Serum leptin levels from the mice (n=36 per group). (D) Intracellular leptin 
levels by western blotting (n=4 per group). (E) Quantification of leptin protein levels from 
panel D normalized to tubulin (n=4 per group). (F) Leptin mRNA levels quantified by 
RT-PCR and normalized to cyclophilin A in adipose tissue from mice fed different 
dietary iron (n=36 per group). (G, H) Leptin expression is significantly decreased in high 
iron-fed transgenic mice expressing the luciferase reporter gene under the control of 
leptin regulatory sequences both in fasting (G) and refed (H) state (n=5 per group). 
*P<0.05 compared to 35 mg/kg dietary iron-fed mice.  
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Figure 2.3 Serum leptin levels in mouse models with increased and decreased 
adipocyte iron. (A) Decreased serum leptin levels in adipocyte-specific ferroportin 
knockout mice (aFpnKO) (n=4 or 5). (B) Body composition in aFpnKO compared to WT 
mice (n=4 or 5). (C) Serum leptin in WT and HFE-/- mice on the 129/SvEvTac 
background fed normal chow (330 mg/kg) and high-iron (20 g/kg) diets (n=10 to 20 per 




   
 
 Figure 2.4 Leptin mRNA and protein levels decrease with iron treatment in primary 
adipocytes or 3T3-L1 adipocytes. (A) Leptin mRNA levels decrease in collagenased 
floating primary adipocytes treated with FAC (n= 4 per group). (B) Intracellular leptin 
protein decreases with FAC treatment. (C) Quantificaton of western blots (total n = 6 
independent determinations) normalized to α-tubulin. (D, E) Leptin-secreted protein (D) 
and mRNA (E) levels in 3T3-L1 cells following 6 h treatment with FAC and FAC plus the 
iron chelator desferoxamine (DFO) (n=3). (F) Dose response for suppression of leptin 




   
 
 Figure 2.5 Iron decreases leptin promoter activity and activates cAMP-response 
element binding protein (CREB). (A) Distal leptin promoter (-5986 bp) -driven luciferase 
activity in the presence or absence of 100 μg/ml FAC (n = 6). (B) Western blot for 
phosphorylation of CREB (p-CREB), total CREB (t-CREB) and α-tubulin in 3T3-L1 
adipocytes treated with 100 μg/ml FAC for 24 h. (C) Quantitation of western blots (total 
n = 3 independent determinations) normalized to α-tubulin (n = 3). (D) Distal leptin 
promoter luciferase activity in 3T3-L1 adipocytes treated with cAMP agonist, 8Br-cAMP 
(1 mM) and/or 100μg/ml FAC for 24 h (n = 6). (E) Distal leptin promoter luciferase 
activity in 3T3-L1 adipocytes treated with cAMP agonist, Forskolin (2 μM) and/or 100 
μg/ml FAC for 24 h (n = 6). (F) Dominant-negative CREB (ACREB) abolished the iron-
mediated decrease of luciferase activity driven by the distal leptin promoter construct (n 
= 6). *P <0.05 compared to control. #P <0.05 compared to untreated group. 
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 Figure 2.6 Iron decreases leptin promoter activity via potential CRE binding sites. (A) 
Iron decreases promoter activity in control and the 425 mutant construct but not the 533 
mutant construct (n = 6). (B) EMSA with the CRE1 oligos as indicated. Unlabeled CRE1 
abolished protein-probe complex formation and mutation of the CRE1 failed to compete 
the protein-probe interaction. (C) EMSA with the CRE2 oligos as indicated. Unlabeled 
CRE2 abolished protein-probe complex formation and mutation of the CRE2 failed to 
compete the protein-probe interaction. Addition of phosphor-CREB (S133) antibody 
markedly decreased CRE2-protein binding. (D) Phosphor-CREB (S133) occupancy at 
leptin promoter sites were induced by iron. Quantitative real-time PCR amplification of 
DNA sequences flanking CRE1 and CRE2 sites from ChIPs performed with pCREB 




   
  
 Figure 2.7 Decreased leptin in mice fed different levels of dietary iron is associated with 
increased food intake. (A) Food intake is positively associated dietary iron levels in mice 
(***P <0.001, n = 69). (B) Real-time recording (upper panel) and accumulation of food 
intake (lower panel) in mice on low (4 mg Fe/kg) and high iron (2000 mg Fe/kg) diets 
(Welcoxon signed-rank test, P = 0.0084 for food intake and P = 0.0002 for accumulated 
food intake, respectively). Black bar in zeitgeber time is night time (12h/daily) and white 
bar is day time (12h/daily). (C, D) Dietary iron association with food intake is abolished 
in ob/ob mice. (E) Significant increase of food intake was observed in 2000 mg/kg 




   
Supplementary experimental procedures 
The leptin UTRs constructs were generously provided by Susan Fried, Boston 
University. The leptin UTRs were cloned into the pGL3 control vector containing SV40 
promoter and enhancer sequences (Promega) to drive a high and stable expression of 
luciferase. UTR plasmids and Renilla as an internal control were nucleofected into well-
differentiated 3T3-L1 preadipocytes using an Amaxa Nucleofector with Kit L (Lonza) 
and an electroperator (Nucleofector II AAD-1001N, device no. 400414; Amaxa 
Biosystems, Cologne, Germany). The proximal 764bp of the murine leptin promoter 
were amplified with BamHI-overhung primers from genomic epididymal fat pad DNA 
and inserted into the pGL4.14 vector (Promega). Plasmids were nucleofected into 
undifferentiated 3T3-L1 preadipocytes using an Amaxa Nucleofector with Kit V (Lonza). 
After overnight incubation, positively transfected cells were selected by hygromycin. 
After 2 weeks’ selection, pools of cells were differentiated and also used to select clonal 
cell lines. Luciferase activity was quantified using the Luciferase Reporter Assay 
System (Promega) and a 96-well plate luminometer. Luciferase levels in different 
constructs were normalized to Renilla or protein levels.  3T3-L1 adipocytes 
differentiated for 10-14 days were starved by DMEM containing 0.5% BSA overnight, 
following by iron treatment. Cyclic AMP or calcium levels were measured by cyclic AMP 
EIA kit or calcium assay kit (Cayman Chemicals Ann Arbor, MI). 
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Figure 2.S1 Serum ferritin levels are inversely associated with serum leptin levels. 
Serum leptin and ferritin levels were measured and correlated in a cohort of patients 




   
 
Figure 2.S2 The association between leptin and BMI or ferritin by quartiles in human. 
(A) Leptin in the high BMI group (upper 25% percentile BMI) is significantly higher than 
that in the other three low BMI groups. (B) The leptin in the high ferritin group (upper 
25% percentile ferritin) is significantly lower than that in the other three low ferritin 
groups (n=65). ***P < 0.001(one way ANOVA for leptin by BMI category); * P < 
0.05(one way ANOVA for leptin by ferritin category). 
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 Figure 2.S3 Serum leptin levels were determined in 5-month-old C57BL/6J mice 
following 9 weeks of being fed low iron (4 mg/kg carbonyl iron), normal chow (35 mg/kg 
and 500 mg/kg), or high iron (2000 mg/kg) diets. Serum leptin decreased with dietary 
iron amounts (linear regression, P  = 0.003) (n =36).  
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Figure 2.S4 Leptin mRNA levels decrease in adipocyte progenitor cells (APC)-derived 
primary adipocytes by fluorescence-activated cell sorting (FACS) (n=3). * P < 0.05 
compared to control (n=6). 
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Figure 2.S5 Iron had no effect on translational regulation of leptin by its 5’- or 3’-UTRs. 
Differentiated 3T3-L1 cells were transiently co-transfected with the chimeric leptin UTR-
LUC constructs and the pRL-TK (Renilla luciferase vector) as described under 
“Supplementary Experimental Procedures” (n=6). Chimeric UTR-LUC constructs 
carrying the 5’-UTR and/or various lengths of 3’-UTR of leptin mRNA (56). The pGL3 
control contained no leptin UTR sequences and was used as control. 
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Figure 2.S6. Proximal leptin promoter (-764bp)-driven luciferase activity is unchanged in 
the presence or absence of 100 μg/ml FAC (n=6).  
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Figure 2.S7 Gene expression with iron and/or 8Br-cAMP treatment. (A) 8Br-cAMP 
abolished increment of ppargac1a expression seen after 6 h iron treatment (n = 3). (B) 
Leptin expression in 3T3-L1 adipocytes treated with cAMP agonist, 8Br-cAMP (1mM), 
and/or 100 μg/ml FAC for 6 h (n = 3). (C) Tfrc mRNA in 3T3-L1 adipocytes treated with 
or without cAMP agonist, 8Br-cAMP (1 mM) for 6 h and no iron or 100 μg/ml FAC for 6 
h (n = 3).  
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Figure 2.S8 cAMP and calcium levels were decreased in FAC treated 3T3-L1 
adipocytes (n = 3). 
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Figure 2.S9 Model of leptin promoter. (A) Mouse leptin promoter and mutagenized 
constructs showing with potential CRE.  (B) Three potential CRE sites and mutagenesis 
used in plasmids or EMSA assay.  
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Figure 2.S10 EMSA with the AP1 oligos as indicated.  
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 Figure 2.S11 Accumulated food intake and body weight in C57/BL6 and ob/ob mice on 
different iron diet. (A) Mice fed with high iron diet (2000 mg/kg) had more food intake 
compared to low iron diet.  (B) Body weights did not change with different dietary iron 
after 9 weeks on diet. *P < 0.05 (1-way ANOVA for food intake in C57BL/6 mice under 
different dietary iron); P = 0.123 (1-way ANOVA for food intake in ob/ob mice under 
different dietary iron), P = 0.524 (1-way ANOVA for body weight in C57BL/6 mice under 
different dietary iron); P = 0.856 (1-way ANOVA for body weight in ob/ob mice under 
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Introduction 
Prior to the current study, there was little evidence that CREB regulates leptin in 
mature adipocytes. It has been reported that activation of CREB during the 
differentiation process suppresses leptin secretion and expression in mesenchymal 
stem cell (1), and bioinformatics analysis indicates there are two potential CRE sites in 
the human ob promoter, but no study of their function has been reported (2). In the 
previous chapter, we have demonstrated that leptin expression can be mediated by 
modulation of CREB. The molecular mechanism for the regulation of leptin by iron 
includes phosphorylation of CREB is demonstrated. However, how iron regulates 
phosphorylation of CREB is totally unknown. Besides iron, another well-know factor that 
can change fuel consumption from glucose to fat burning in mammals is fasting. Leptin 
is responsive to nutritional status and fasting leads to a gradual decline in leptin (3, 4). 
The cellular mechanism that causes leptin to fall with iron may be similar to that seen 
with fasting. Fasting evokes a number of responses, including an increase of glucagon, 
a known activator of CREB (5). Thus, CREB may play a role in connecting not only iron 
but also nutritional status to leptin. Interestingly, in this study, we have found that 
nutrient-sensing pathway, the hexosamine biosynthesis pathway (HBP), which is also 
known to play a crucial role in regulation of CREB (6) and has been reported to regulate 
leptin expression (7), also contributes to iron-induced changes in leptin expression.  
In this chapter, I will explore the relationship of iron, O-GlcNAcylation, and leptin, 
trying to establish the role of micronutrition status in metabolic regulation.  
Methods 
Experimental animals. Dietary iron manipulations were accomplished with diets 
containing 60% carbohydrate, 17.7% protein, and 7.2% fat by weight, and either 35 
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mg/kg (TD. 10211) or 2 g/kg carbonyl iron (TD. 10214) (Harlan Teklad) for a period of 2 
months before phenotyping. Wild-type (WT) mice were of the C57BL6/J strain.  
Reagents and assays. Reagents were purchased from Sigma-Aldrich unless 
otherwise noted. Serum leptin levels were measured by ELISA kit (Millipore).  
3T3-L1 adipocyte culture and differentiation. 3T3-L1 adipocytes (ATCC) were 
maintained in high-glucose DMEM (HG-DMEM) supplemented with 10% bovine calf 
serum (BCS, Hyclone) and penicillin/streptomycin (Invitrogen). For differentiation (8), 
cells were incubated in HG-DMEM with 10% BCS for 48 h after confluence. Cells were 
then cultured in differentiation medium I (HG-DMEM, 10% FBS, 1 μg/ml insulin, 0.25 
μg/ml dexamethasone, 0.5 mM IBMX, 4 μM ciglitazone) for 4 days, followed by 
differentiation medium II (HG-DMEM, 10% FBS, 1 μg/ml insulin) for 48 h. Prior to 
experiments, cells were cultured overnight in DMEM (Invitrogen) with 0.5% BSA. All 
experiments were performed in MEM-α medium, which is iron-free, supplemented with 
10% FBS. 
Plasmids, nucleofection, and luciferase assay. The proximal 5,986bp of the 
murine leptin promoter were amplified with BglII-overhung or HindIII-overhung primers 
from genomic epididymal fat pad DNA and inserted into the pGL4.14 vector (Promega). 
Site-specific mutagenesis studies were carried out using QuikChange Lightning Multi 
Site-Directed Mutagenesis Kit (Agilent Technologies). Plasmids were nucleofected into 
undifferentiated 3T3-L1 preadipocytes using an Amaxa Nucleofector with Kit V (Lonza) 
and an electroperator (Nucleofector II AAD-1001N, device no. 400414; Amaxa 
Biosystems, Cologne, Germany). After overnight incubation, positively transfected cells 
were selected by hygromycin. After 2 weeks’ selection, pools of cells were differentiated 
and also used to select clonal cell lines. Luciferase activity was quantified using the 
Luciferase Reporter Assay System (Promega) and a 96-well plate luminometer. 
Luciferase levels of specific genes were normalized to protein levels.  
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Quantification of transcripts. Quantitative RT-PCR was performed as described 
previously (9). Briefly, mRNA was extracted from primary or 3T3-L1 adipocytes or fat 
pad using TRIzol (Invitrogen), purified using an RNeasy column (QIAgen), and 
synthesized into cDNA using a First-Strand cDNA Synthesis Kit (Invitrogen). The fat 
cake in TRIzol was cleared by transferring the infranatant to a clean tube using a glass 
syringe before extraction. Real-time PCR was performed with a QuantStudio™ Real-
Time PCR Systems (Applied Biosystems). cDNA products were quantified using the 
relative standard curve method. mRNA levels of specific genes were normalized to 
cyclophilin A or RPL13A. 
Antibodies. Antibodies used included pCREB (Ser 133) (87G3) and CREB 
(86B10) from Cell signaling Inc., ob (A20, sc842) from Santa Cruz Inc., anti-O-Linked 
N-Acetylglucosamine antibody (10) (ab2739) from Abcam Inc., CTD 110.6 from 
Covance, and α-tubulin (T9026) from Sigma-Aldrich.  
Immunoprecipitations (IP) assay. Well-differentiated adipocytes were washed 
with PBS once and collected in lysis buffer with protease inhibitor (Roche Complete 
Tablet 11836153001) and phosphatase inhibitor (sigma P2850). After centrifugation at 
15000 rpm for 10 min, the supernatant was transferred to a new tube and protein 
concentration was measured. The lysates (600ug) were immunoprecipitated with 4ug of 
CREB antibody (Cell signaling) at 4°C for overnight and added with 100 μl of (50% 
slurry) Protein A agarose beads (Millipore) overnight after precleared with 20 μl of free 
protein A agarose beads (Millipore) for 2 h. The supernatant was discard and the 
immune complex on beads was washed with lysis buffer with protease inhibitor and 
phosphatase inhibitor 3 times and boiled in sample buffer. The immunoprecipitated 
products were subjected to 7.5% SDS-PAGE, transferred onto the membrane, and 
immunoblotted with the antibodies, RL-2 and phosphor-CREB. 
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Statistics. Descriptive statistics in the text and figures are represented as 
average ± SEM. An unpaired 2-tailed Student’s t test was used to determine 
significance between controls and individual experimental groups. One-way ANOVA 
was used to compare series of data. p < 0.05 was considered significant for all tests. All 
statistical analyses were performed with STATA.  
Study approval. Animal studies were approved by the Institutional Animal Care 
and Use Committee of the University of Utah, under IACUC approval A3031-01.  
Results and discussion 
Dietary iron overload decreases O-GlcNAcylated protein level. To explore the 
regulation of dietary iron’s effect on O-GlcNAcylation, we first measured the O-
GlcNAcylated protein in epydidymal white adipose tissue by western blots. We 
observed a decrease of O-GlcNAcylated protein in fat from mice fed a high iron diet 
(2000 mg/kg iron) compared with that in mice fed low normal chow (35 mg/kg iron) 
(Figure 3.1A). We also demonstrated that adipocyte iron levels respond to dietary iron 
content in WT C57BL6/J mice by measuring mRNA levels of the transferrin receptor 
(Tfrc). Tfrc mRNA contains iron response elements in its 3’ untranslated region (UTR) 
that result in decreased Tfrc mRNA levels as cellular iron levels increase (11). W 
observed a decrease of Tfrc mRNA in fat pad from high iron diet-fed mice compared 
with that in mice fed the normal iron chow (35 mg/kg or 500mg/kg iron) (Chapter 2, 
Figure 2.2B, P < 0.05). Serum leptin decreased with dietary iron (Chapter 2, Figure 
2.S3). We also supplemented FAC to the medium and measured the total O-
GlcNAcylation levels. We found a decrease of O-GlcNAcylated protein in well-
differentiated adipocytes (Figure 3.2A and 3.2B).  
OGA+/- mice relieved decreased serum leptin in high iron diet mice. To 
investigate the effect of iron and O-GlcNAcylation on leptin, OGA heterozygous mice 
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were fed the low normal or high iron diets (35 mg/kg vs 2000 mg/kg iron). We then 
measured the leptin in the serum from those mice. High iron diet decreased serum 
leptin in wild-type mice (Figure 3.3A, P < 0.05). We found leptin level was higher in 
OGA+/- mice in high iron diet (Figure 3.3A). This finding is consistant with our previous 
in vitro data in human adipocytes, suggesting increased O-GlcNAcylation plays a role in 
increase of leptin (12). We also found the decreased serum leptin in high iron diet-fed 
wild-type mice was relieved in OGA+/- mice independent of epididymal fat pad mass 
(Figure 3.3A and 3.3B). In 3T3-L1 adipocytes, glucosamine treatment relieved 
decreased leptin promoter activity by iron (Figure 3.4). Iron’s effect on leptin promoter 
activity was abolished when co-treated with GFAT inhibitor, 6-diazo-5-oxo-L-norleucine 
(DON) (Figure 3.5). 
Decreased O-GlcNAcylation of CREB is associated with increased phosphp-
CREB in iron-treated 3T3-L1 adipocytes. We have preciously demonstrated activation 
of CREB by agonist blunted iron’s effect on leptin reduction; similarly dominate-negative 
CREB, A-CREB, is also sufficient to block iron’s effect on leptin, suggesting iron-
mediated phosphorylation of CREB may be responsible for leptin regulation. Previously, 
it has been shown that crosstalk between phosphorylation and O-GlcNAcylation of 
CREB can modulate CREB activity to CRE-mediated promoter activity. We then 
measure iron’s effect on CREB post-modification.  
When we pulled down the CREB, and found iron supplementation to 3T3-L1 
adipocytes decreased O-GlcNAcylation of CREB and total CREB protein while 
increased phospho-CREB levels (Figure 3.6). Decreased total CREB may be due to 
phosphorylation of CREB increase its degradation by protease (13, 14). Turnover of 
other transcriptional regulators including β-catenin and I-κB (15, 16) are also regulated 
through phosphorylation-targeted proteasomal degradation. Namely, increased 
phosphorylation of CREB is associated with a decrease of O-GlcNAcylation of CREB, 
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and activation of the HBP by glucosamine overcomes the iron-induced inhibition of 
leptin. These observations further underline the close relationship of iron levels with 
overall nutritional status and metabolic regulation. 
In sum, the current results demonstrate that adipocytes serve to integrate not 
only the nutrient status, but also the iron status of the organism to modulate 
metabolism, appetite, and energy homeostasis. Presumably, this would help maintain 
food-seeking behavior in an iron-rich environment that would support high rates of 
oxidative metabolism, energy production, growth, and reproduction. The adipocyte 
responding to iron availability and adjusting expression of adipokines related to 
metabolism make it well suited to perform its broader nutrient-sensing function. 
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Figure 3.1 Dietary iron supplementation decreased O-GlcNacylation in adipose tissue.  




Figure 3.2 Iron treatment decreased total O-GlcNAcylation in 3T3-L1 adipocytes. (A) 
Whole O-GlcNAcylated protein decreases with 100μg/ml FAC treatment. (B) 
Quantificaton of western blots (total n = 3 independent determinations) normalized to α-
tubulin. Significance denoted *P < 0.05 using Two-tailed Student’s t tests (A). Data 
represent mean ± SEM. 
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Figure 3.3 Decreased serum leptin under high iron diet is relieved in OGA+/- mice 
relieved. (A) High iron diet decreased serum leptin in wild-type mice, while the decrease 
of leptin is relieved in OGA+/- mice.  (B) No difference in epididymal fat mass was 
observed in both wild-type and OGA+/- mice under 35 mg/kg and 2000 mg/kg iron diet. 
Significance denoted *P < 0.05 using Two-tailed Student’s t tests (A). Data represent 
mean ± SEM. 
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Figure 3.4 Glucosamine relieved decreased serum leptin promoter activity in 3T3-L1 
adipocytes by iron. Significance denoted *** P < 0.001 using Two-tailed Student’s t 
tests. Data represent mean ± SEM. 
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Figure 3.5 GFAT inhibitor, 6-diazo-5-oxo-L-norleucine (DON), abolished FAC-mediated 
decreased serum leptin promoter activity in 3T3-L1 adipocytes.  
    
93 
 
   
Figure 3.6 Decreased O-GlcNAc-CREB is associated with increased phospho-CREB 
with iron treatment in 3T3-L1 adipocytes. Total-CREB antibody was used in 
immunoprecipitation, and blot for phosphor-CREB and O-GlcNAcylated-CREB protein 
by RL2 antibody.  
 
    
94 
References 
1. Yang, D.C., Tsay, H.J., Lin, S.Y., Chiou, S.H., Li, M.J., Chang, T.J., and Hung, 
S.C. 2008. cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG 
mRNA expression in mesenchymal stem cells by suppressing leptin. PLoS One 
3:e1540. 
 
2. Gong, D.W., Bi, S., Pratley, R.E., and Weintraub, B.D. 1996. Genomic structure 
and promoter analysis of the human obese gene. J Biol Chem 271:3971-3974. 
 
3. Fried, S.K., Ricci, M.R., Russell, C.D., and Laferrere, B. 2000. Regulation of 
leptin production in humans. J Nutr 130:3127S-3131S. 
 
4. Wang, J., Liu, R., Hawkins, M., Barzilai, N., and Rossetti, L. 1998. A nutrient-
sensing pathway regulates leptin gene expression in muscle and fat. Nature 393:684-
688. 
 
5. Altarejos, J.Y., and Montminy, M. 2011. CREB and the CRTC co-activators: 
sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 12:141-151. 
 
6. Rexach, J.E., Clark, P.M., Mason, D.E., Neve, R.L., Peters, E.C., and Hsieh-
Wilson, L.C. 2012. Dynamic O-GlcNAc modification regulates CREB-mediated gene 
expression and memory formation. Nat Chem Biol 8:253-261. 
 
7. McClain, D.A., Lubas, W.A., Cooksey, R.C., Hazel, M., Parker, G.J., Love, D.C., 
and Hanover, J.A. 2002. Altered glycan-dependent signaling induces insulin resistance 
and hyperleptinemia. Proc Natl Acad Sci U S A 99:10695-10699. 
 
8. Chen, Z., Torrens, J.I., Anand, A., Spiegelman, B.M., and Friedman, J.M. 2005. 
Krox20 stimulates adipogenesis via C/EBPbeta-dependent and -independent 
mechanisms. Cell Metab 1:93-106. 
 
9. Huang, J., Gabrielsen, J.S., Cooksey, R.C., Luo, B., Boros, L.G., Jones, D.L., 
Jouihan, H.A., Soesanto, Y., Knecht, L., Hazel, M.W., et al. 2007. Increased glucose 
disposal and AMP-dependent kinase signaling in a mouse model of hemochromatosis. 
J Biol Chem 282:37501-37507. 
 
10. Taylor, R.P., Geisler, T.S., Chambers, J.H., and McClain, D.A. 2009. Up-
regulation of O-GlcNAc transferase with glucose deprivation in HepG2 cells is mediated 
by decreased hexosamine pathway flux. J Biol Chem 284:3425-3432. 
 
11. Casey, J.L., Hentze, M.W., Koeller, D.M., Caughman, S.W., Rouault, T.A., 
Klausner, R.D., and Harford, J.B. 1988. Iron-responsive elements: regulatory RNA 
sequences that control mRNA levels and translation. Science 240:924-928. 
 
12. Considine, R.V., Cooksey, R.C., Williams, L.B., Fawcett, R.L., Zhang, P., 
Ambrosius, W.T., Whitfield, R.M., Jones, R., Inman, M., Huse, J., et al. 2000. 
Hexosamines regulate leptin production in human subcutaneous adipocytes. J Clin 
Endocrinol Metab 85:3551-3556. 
 
    
95 
13. Tan, Y.W., Zhang, S.J., Hoffmann, T., and Bading, H. 2012. Increasing levels of 
wild-type CREB up-regulates several activity-regulated inhibitor of death (AID) genes 
and promotes neuronal survival. BMC Neurosci 13:48. 
 
14. Taylor, C.T., Furuta, G.T., Synnestvedt, K., and Colgan, S.P. 2000. 
Phosphorylation-dependent targeting of cAMP response element binding protein to the 
ubiquitin/proteasome pathway in hypoxia. Proc Natl Acad Sci U S A 97:12091-12096. 
 
15. Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G.H., Tan, Y., Zhang, Z., Lin, X., 
and He, X. 2002. Control of beta-catenin phosphorylation/degradation by a dual-kinase 
mechanism. Cell 108:837-847. 
 
16. Chen, Z., Hagler, J., Palombella, V.J., Melandri, F., Scherer, D., Ballard, D., and 
Maniatis, T. 1995. Signal-induced site-specific phosphorylation targets I kappa B alpha 
to the ubiquitin-proteasome pathway. Genes Dev 9:1586-1597.







It is well-established that iron overload is associated with insulin resistance and 
development of diabetes (1). Because adiponectin is an insulin-sensitizing adipokine, it 
is reasonable to speculate that iron stores might result in decreased levels of 
adiponectin. Scientific reports have also investigated the role of iron in the regulation of 
appetite. Dietary iron supplementation, for example, is associated with growth and 
increased appetite in children (12, 13). 
In this dissertation, we have therefore investigated the effect of iron on 
adiponectin and leptin, and the mechanism of iron-induced decreases in the levels of 
these adipokines. We first verified that the concentration of circulating ferritin, a marker 
of iron stores, is associated with low serum adiponectin and leptin in humans. We 
demonstrate in humans that the association between serum ferritin and adiponectin or 
leptin is independent of inflammation. And serum ferritin, even within its normal ranges, 
is among the best predictors of serum adiponectin or leptin. Similarly, mice fed a high 
iron diet and 3T3-L1 adipocytes treated with iron exhibited decreased adiponectin and 
leptin mRNA and protein.  
We found that iron negatively regulates transcription of adiponectin promoter-
driven luciferase activity in a FOXO1-dependent manner. However, iron decreases the 
inactivation form of FOXO1, acetyl-FOXO1, while leaving phosphorylated FOXO1 and 
total FOXO1 unaffected. The mechanism of iron decreased adiponectin and promotion 
of metabolic syndrome is demonstrated via the binding affinity of multiple transcription 
factors to the adiponectin promoter by ChIP studies. The higher activation of FOXO1 in 
iron-treated cells contributes to more inactivation of PPARγ through directly interaction, 
leading to decreased adiponectin transcription and expression. These findings directly 
    
97 
demonstrate a causal role for iron as a risk factor for metabolic syndrome and a role for 
adipocytes in modulating metabolism through adiponectin in response to iron stores.  
We also demonstrate that transcription of leptin also responds to iron. 
Consistent with the changes in leptin, dietary iron content was also directly related to 
food intake, independently of weight. Loss of the adipocyte iron export channel, 
ferroportin, in mice resulted in adipocyte iron loading and decreased leptin. Conversely, 
decreased levels of hepcidin in hereditary hemochromatosis result in increased 
adipocyte ferroportin expression, decreased adipocyte iron, and increased leptin. 
Treatment of 3T3-L1 adipocytes with iron decreased leptin mRNA levels in a dose-
dependent manner. We found iron negatively regulated leptin transcription via cAMP 
response element binding protein (CREB) activation. Two potential CREB-binding sites 
were identified in the mouse leptin promoter region. Mutation of both sites completely 
blocked the effect of iron on promoter activity.  
Iron also negatively regulates O-GlcNAc modification both in 3T3-L1 and 
epidydimal fat, and mice heterozygous for deletion of the gene encoding the enzyme 
that removes O-GlcNAc, O-GlcNAcase, showed significantly increased serum leptin 
compared to wild-type mice. Glucosamine treatment rescued high iron-induced 
decrease of leptin promoter activity. These results suggest that the effects of iron on 
leptin may be via crosstalk of O-GlcNAcylation and phosphorylation of CREB. These 
findings indicate that levels of dietary iron play an important role in regulation of appetite 
and fat metabolism through CREB-dependent modulation of leptin expression.  
